Toxicology – Penicillamine

Core Concept

D-penicillamine is an oral chelating agent that forms complexes with certain metals and increases their urinary elimination.

Its major established modern role is long-term copper removal in Wilson disease. Although historically used for lead, mercury, and arsenic poisoning, it is generally not a preferred first-line chelator for these toxic exposures today because better-supported and often better-tolerated alternatives are available.

Mechanism of Action

Penicillamine contains a reactive sulfhydryl (-SH) group capable of binding selected metal ions.

This produces relatively soluble:

Metal + penicillamine → chelated complex → urinary excretion

The result is increased elimination of the chelatable metal and gradual reduction of body burden.

Its effectiveness varies substantially according to:

• Metal involved
• Chemical species of the metal
• Distribution into tissues
• Duration of exposure
• Renal function
• Availability of alternative chelators

Major Uses

Penicillamine has been used for:

• Wilson disease
• Selected copper toxicity
• Lead poisoning
• Mercury poisoning
• Arsenic poisoning
• Cystinuria

It was also historically used as a disease-modifying drug for rheumatoid arthritis, but safer and more effective therapies have largely displaced it for that indication.

Wilson Disease

Wilson disease is an inherited disorder of copper metabolism caused by pathogenic variants affecting ATP7B.

Impaired biliary copper excretion causes progressive copper accumulation, particularly in the:

• Liver
• Brain
• Cornea
• Other tissues

Clinical manifestations may include:

• Hepatitis
• Cirrhosis
• Acute liver failure
• Tremor
• Dystonia
• Dysarthria
• Parkinsonian features
• Psychiatric or behavioral changes
• Hemolytic anemia

Role in Wilson Disease

Penicillamine binds copper and increases its urinary excretion.

It remains an established copper-chelating option, although trientine is an important alternative and may be preferred in some patients because of tolerability.

Long-term management may involve:

• Copper chelation
• Zinc therapy in selected circumstances
• Dietary counseling
• Serial biochemical monitoring
• Specialist hepatology/neurology care

Treatment is usually prolonged because the underlying genetic defect persists.

Neurologic Worsening in Wilson Disease

An important complication of initiating copper chelation is paradoxical neurologic deterioration.

Patients with neurologic Wilson disease can occasionally develop worsening:

• Tremor
• Dystonia
• Dysarthria
• Rigidity
• Other neurologic abnormalities

after chelation begins.

Treatment therefore requires specialist supervision and careful adjustment rather than aggressive unsupervised escalation.

Acute Copper Poisoning

Acute copper salt ingestion can cause:

• Severe gastrointestinal irritation
• Vomiting
• Abdominal pain
• Gastrointestinal bleeding
• Hemolysis
• Methemoglobinemia in some cases
• Hepatic injury
• Acute kidney injury
• Shock

Penicillamine has been used, but evidence for its role in severe acute copper poisoning is limited.

Initial management centers on stabilization and specialist toxicology guidance.

Lead Poisoning

Penicillamine was historically used as an oral chelator for lead.

Modern practice generally favors:

• Succimer for many patients requiring oral chelation
• Calcium disodium EDTA (CaNa₂EDTA) for selected more severe poisoning
• Dimercaprol plus CaNa₂EDTA in selected severe lead encephalopathy

Therefore:

Penicillamine is not a routine first-line chelator for modern lead poisoning.

Lead Encephalopathy

Lead encephalopathy may produce:

• Persistent vomiting
• Altered mental status
• Ataxia
• Seizures
• Cerebral edema
• Coma

This is a medical emergency requiring parenteral chelation and intensive supportive care.

Penicillamine should not replace established emergency chelation regimens in severe lead encephalopathy.

Blood Lead Concentration

Modern lead management is based on:

• Confirmed venous blood lead concentration
• Symptoms
• Patient age
• Exposure source
• Presence of encephalopathy
• Renal function
• Ability to receive oral therapy

Historical automatic repeat-chelation thresholds should not be applied rigidly.

Source Removal in Lead Poisoning

Chelation cannot compensate for continued exposure.

Possible sources include:

• Lead-based paint and dust
• Contaminated soil
• Occupational exposure
• Traditional remedies
• Cosmetics
• Contaminated spices or products
• Ceramics or cookware
• Retained lead-containing foreign material

Identifying and stopping exposure is fundamental treatment.

Mercury Poisoning

The role of chelation depends strongly on the form of mercury.

Important forms include:

• Elemental mercury
• Inorganic mercury salts
• Organic mercury compounds such as methylmercury

These differ greatly in absorption, tissue distribution, and toxicity.

Penicillamine and Mercury

Penicillamine has historically been used for mercury poisoning, but it is generally no longer a preferred chelator.

Depending on the mercury species and clinical circumstances, agents such as:

• Succimer (DMSA)
• DMPS, where available

are generally more relevant modern options.

Not every elevated mercury measurement requires chelation.

Urinary Mercury Measurements

A major limitation of the older approach is reliance on urinary mercury excretion as a direct measure of total body burden.

Urine testing is most useful for certain elemental or inorganic exposures.

It is less informative for some organic mercury exposures.

Furthermore:

An increased urine metal concentration after a chelator does not by itself prove clinically significant poisoning.

Avoid Chelation Challenge Tests

So-called “provoked” urine testing involves administering a chelator and then measuring urinary metal excretion.

This approach is not recommended for diagnosing heavy-metal poisoning.

Chelators predictably increase urinary metal excretion, making reference ranges for unprovoked specimens inappropriate.

Diagnosis should be established using validated exposure-specific testing before chelation is considered.

Arsenic Poisoning

Acute inorganic arsenic toxicity can cause:

• Severe vomiting and diarrhea
• Volume depletion
• Hypotension
• QT abnormalities
• Ventricular dysrhythmias
• Encephalopathy
• Metabolic abnormalities
• Multiorgan dysfunction

Delayed manifestations can include:

• Peripheral neuropathy
• Bone-marrow abnormalities
• Skin and nail changes

Penicillamine and Arsenic

Penicillamine has historical use as an alternative chelator, but it is not a preferred modern treatment for significant arsenic poisoning.

More established options include:

• Dimercaprol in selected severe acute poisoning
• Succimer
• DMPS where available

Choice depends on severity, formulation, clinical status, and local availability.

Arsenic Testing

Urinary arsenic can be useful, but interpretation requires care.

Recent seafood consumption can markedly elevate total urinary arsenic because seafood contains relatively nontoxic organic arsenic compounds.

When relevant, arsenic speciation helps distinguish toxicologically important inorganic species and metabolites from seafood-derived organic arsenic.

Treatment should not be stopped or continued solely according to an old universal urine threshold.

Renal Function

Metal-penicillamine complexes are largely eliminated through the kidneys.

Renal dysfunction therefore complicates treatment and may increase adverse effects.

More importantly, penicillamine itself can cause renal disease.

Monitoring is required during sustained treatment.

Penicillamine-Induced Renal Toxicity

Important manifestations include:

• Proteinuria
• Hematuria
• Glomerular injury
• Nephrotic syndrome

Development of significant renal abnormalities may require treatment modification or discontinuation.

Bone-Marrow Toxicity

Penicillamine can cause potentially serious hematologic toxicity, including:

• Leukopenia
• Thrombocytopenia
• Agranulocytosis
• Aplastic anemia

Patients receiving ongoing therapy require periodic complete blood counts.

Unexplained fever, infection, bruising, or bleeding warrants prompt evaluation.

Autoimmune Complications

Penicillamine can trigger several immune-mediated disorders.

Reported complications include:

• Myasthenia gravis
• Lupus-like syndromes
• Pemphigus
• Vasculitis
• Other autoimmune phenomena

These adverse effects are particularly relevant during chronic therapy.

Pulmonary Toxicity

Rare but important complications include:

• Interstitial pulmonary disease
• Alveolitis
• Pulmonary hemorrhage

New respiratory symptoms during therapy warrant investigation.

Neurologic and Ocular Effects

Reported complications include:

• Peripheral neuropathy
• Optic neuropathy
• Neuromuscular weakness

These findings may be difficult to distinguish from manifestations of the underlying metal toxicity or Wilson disease.

Gastrointestinal and Hepatic Effects

Possible adverse effects include:

• Nausea
• Vomiting
• Reduced appetite
• Altered taste
• Gastrointestinal discomfort
• Hepatic injury

Tolerability is one reason alternative chelators may be selected.

Hypersensitivity

Penicillamine can produce:

• Rash
• Fever
• Drug hypersensitivity reactions

Severe hypersensitivity requires discontinuation and appropriate treatment.

Penicillin Allergy – Important Correction

Despite its name and chemical origin:

Penicillamine is not penicillin.

The older claim that penicillin allergy automatically contraindicates penicillamine is too absolute.

Cross-reactivity is not equivalent to that of beta-lactam antibiotics, although patients with previous significant drug hypersensitivity still require careful assessment.

A history of penicillin allergy alone should not automatically be treated as an absolute contraindication.

Pyridoxine (Vitamin B6)

Penicillamine can interfere with pyridoxine metabolism.

Supplementation may therefore be considered during prolonged treatment, particularly in:

• Wilson disease
• Malnutrition
• Other states associated with increased deficiency risk

Short courses of chelation do not necessarily require routine supplementation in every patient.

Drug Interactions

Concurrent treatment with other drugs capable of producing:

• Bone-marrow suppression
• Renal injury
• Significant immunosuppression

may increase toxicity.

Medication review is therefore important before and during prolonged therapy.

Pregnancy

The historical FDA Category D classification is obsolete.

Penicillamine crosses the placenta and has potential fetal risks, but abruptly stopping effective treatment for Wilson disease can also cause serious maternal deterioration.

Management during pregnancy should therefore be individualized with specialist input.

The goal is to maintain adequate control of maternal copper metabolism while minimizing fetal and maternal treatment risks.

Monitoring During Long-Term Therapy

Monitoring may include:

• CBC
• Urinalysis
• Renal function
• Liver tests
• Clinical neurologic assessment
• Copper indices in Wilson disease
• Assessment for hypersensitivity and autoimmune complications

The specific schedule depends on indication and duration.

Chelation Does Not Replace Supportive Care

Chelation is only one component of heavy-metal management.

Important principles remain:

Stop exposure → stabilize the patient → identify the metal and chemical species → assess organ injury → use a validated chelator only when indicated

Chelation should not be started solely because a nonspecific laboratory test reports an elevated “metal burden.”

Important Modernization of the Older Source

• Penicillamine is an oral sulfhydryl-containing chelator that increases urinary elimination of selected metals.
• Its major established role is long-term copper chelation in Wilson disease.
• Trientine is an important alternative for Wilson disease and may be preferred in some patients.
• Neurologic Wilson disease can initially worsen after chelation begins.
• Penicillamine is not a preferred first-line treatment for lead poisoning; succimer and CaNa₂EDTA have better-established modern roles.
• Severe lead encephalopathy requires established parenteral chelation rather than relying on penicillamine.
• Penicillamine is generally not preferred for mercury poisoning; succimer or DMPS may be more appropriate depending on mercury species.
• It is also not a preferred modern chelator for significant arsenic poisoning.
• Heavy-metal treatment should not be based solely on old rigid blood or urine thresholds.
• Urinary metal concentrations must be interpreted according to the specific metal and exposure.
• Provoked urine metal testing should not be used to diagnose poisoning.
• Seafood can substantially confound total urinary arsenic measurements; speciation may be necessary.
• Penicillamine can cause serious renal, hematologic, autoimmune, pulmonary, neurologic, and hypersensitivity toxicity.
• Periodic CBC, urinalysis, and renal assessment are important during prolonged treatment.
• Penicillin allergy is not automatically an absolute contraindication to penicillamine.
• Pyridoxine supplementation may be appropriate during prolonged therapy.
• Historical FDA pregnancy letter categories are obsolete.
• Exact chelation regimens should be determined by current toxicology or disease-specific protocols.

Key Points

• Penicillamine binds selected metals and promotes their urinary elimination.
• Its most important contemporary use is Wilson disease.
• It has historical roles in lead, mercury, and arsenic poisoning, but generally is not the preferred modern chelator for these exposures.
• Identify and stop the source of metal exposure before expecting chelation to succeed.
• The chemical form of a metal matters; “mercury poisoning,” for example, is not a single uniform toxicologic entity.
• Do not diagnose heavy-metal poisoning using chelator-provoked urine testing.
• Penicillamine can itself cause serious toxicity, especially proteinuria/nephrotic syndrome and bone-marrow suppression.
• Chronic treatment requires laboratory and clinical monitoring.
• Treatment decisions should be based on validated metal measurements, symptoms, organ injury, exposure history, and specialist toxicology guidance rather than an isolated laboratory value.

Toxicology – N-Acetylcysteine (NAC)

Core Concept

N-acetylcysteine (NAC) is the specific antidotal treatment for clinically important acetaminophen (paracetamol) poisoning.

Its major protective effect is restoration of glutathione, allowing detoxification of the reactive acetaminophen metabolite NAPQI.

NAC is most effective when started early, but an important principle is:

Late presentation is not a reason to withhold NAC when acetaminophen-related hepatic injury is suspected.

Normal Acetaminophen Metabolism

At therapeutic exposure, most acetaminophen undergoes hepatic conjugation through:

• Glucuronidation
• Sulfation

A smaller fraction is oxidized by cytochrome P450 enzymes, particularly CYP2E1, producing:

N-acetyl-p-benzoquinone imine (NAPQI)

NAPQI is highly reactive.

Role of Glutathione

Under normal conditions:

NAPQI + glutathione → nontoxic conjugates

Therefore, only a small amount of reactive NAPQI normally remains available to injure hepatocytes.

What Happens in Overdose

Following a sufficiently large exposure:

Conjugation pathways become overwhelmed → proportion metabolized to NAPQI increases → glutathione stores fall

Once detoxification capacity becomes inadequate:

NAPQI binds cellular proteins → mitochondrial oxidative injury → hepatocyte necrosis

The centrilobular region of the liver is particularly vulnerable.

How NAC Works

NAC protects through several mechanisms.

1. Glutathione restoration

NAC provides cysteine, a rate-limiting substrate for glutathione synthesis.

This restores the liver’s ability to detoxify NAPQI.

2. Alternative sulfur substrate

Early after overdose, NAC can favor safer acetaminophen metabolism through sulfation-related pathways.

3. Direct reducing effects

NAC has antioxidant and reducing properties that may limit oxidative injury.

4. Benefit in established liver injury

Even after most acetaminophen has been metabolized, NAC can still provide benefit through effects on:

• Oxidative stress
• Mitochondrial function
• Hepatic microcirculation
• Tissue oxygen delivery

This explains why NAC remains useful in late presenters with acetaminophen-induced acute liver failure.

Timing of NAC

NAC provides its greatest protection when started within approximately 8 hours of a significant acute overdose.

However:

Do not interpret the 8-hour concept as a treatment cutoff.

Patients presenting later can still benefit substantially.

Do Not Delay NAC When Risk Is Significant

If a potentially toxic acute ingestion occurred and the acetaminophen concentration will not be available before the period when early NAC is most effective, treatment is commonly started while awaiting results.

NAC can subsequently be discontinued if appropriate evaluation demonstrates that continued treatment is unnecessary.

Rumack–Matthew Nomogram

The nomogram estimates hepatotoxicity risk after a specific type of exposure:

A single, acute acetaminophen ingestion with a reasonably known ingestion time.

A properly timed serum acetaminophen concentration is plotted against time since ingestion.

If the concentration reaches the applicable treatment line, NAC is indicated.

When the Nomogram Can Be Used

The classic nomogram is designed for concentrations obtained from approximately:

4 to 24 hours after a single acute ingestion

A level obtained too early may not represent peak absorption.

When the Nomogram Should NOT Be Used

Do not apply the Rumack–Matthew nomogram to:

• Unknown ingestion time
• Repeated supratherapeutic ingestion
• Chronic excessive use
• Staggered ingestion over an extended period
• Patients already presenting with established hepatic injury

These situations require different clinical assessment.

Modified-Release Acetaminophen

Extended- or modified-release products can produce delayed or prolonged absorption.

Similarly, coingestion of drugs that slow gastrointestinal motility may alter absorption.

A single early concentration can therefore occasionally be misleading.

Selected patients require repeat acetaminophen concentrations rather than relying on one measurement.

Unknown Time of Ingestion

When the time cannot be established reliably, the nomogram cannot be interpreted correctly.

Assessment should instead incorporate:

• Detectable acetaminophen concentration
• AST and ALT
• Clinical history
• Evidence of hepatic injury
• Other laboratory abnormalities

When clinically meaningful exposure remains possible, NAC is generally favored while the evaluation continues.

Repeated Supratherapeutic Ingestion

Repeated excessive acetaminophen use differs from a single acute overdose.

The nomogram is not valid.

Evaluation generally includes:

• Serum acetaminophen
• AST
• ALT
• Exposure history
• Risk factors and clinical condition

NAC is appropriate when laboratory findings or exposure circumstances suggest clinically important acetaminophen toxicity.

Late Presentation

A patient may present after the serum acetaminophen concentration has become very low or undetectable.

This does not exclude acetaminophen toxicity.

If the patient has compatible acute hepatic injury after a credible exposure:

NAC should be started or continued despite an undetectable acetaminophen concentration.

Clinical Course of Acetaminophen Poisoning

The clinical course is traditionally divided into stages, although individual patients may not follow them precisely.

Early phase

Possible:

• Nausea
• Vomiting
• Malaise
• Diaphoresis

Some patients are completely asymptomatic.

Developing hepatic injury

Over the next day or several days:

• AST/ALT rise
• Right upper quadrant discomfort may develop
• INR may increase

Severe toxicity

Possible:

• Massive aminotransferase elevation
• Coagulopathy
• Hypoglycemia
• Lactic/metabolic acidosis
• Encephalopathy
• Acute kidney injury
• Multiorgan failure

Recovery

Survivors may undergo substantial hepatic regeneration over subsequent days to weeks.

Acute Liver Failure

Severe acetaminophen toxicity can produce:

• Coagulopathy
• Encephalopathy
• Hypoglycemia
• Lactic acidosis
• Acute kidney injury
• Cerebral edema in advanced acute liver failure

These patients require intensive care and early involvement of a liver-transplant center when appropriate.

NAC should generally continue while clinically significant acetaminophen-associated liver failure persists.

Laboratory Evaluation

Depending on presentation, useful investigations include:

• Serum acetaminophen concentration
• AST
• ALT
• INR/PT
• Bilirubin
• Creatinine
• Electrolytes
• Glucose

In severe illness, additional testing may include:

• Blood gas
• Lactate
• Phosphate
• Serial renal and hepatic studies

Serum Acetaminophen Concentration

Interpret the concentration in context.

Important questions include:

• Was this a single acute ingestion?
• Is the ingestion time reliable?
• Was the sample drawn at least several hours afterward?
• Was a modified-release preparation involved?
• Were gastrointestinal-motility-slowing drugs coingested?
• Is there already hepatic injury?

The number alone does not answer these questions.

Oral vs Intravenous NAC

NAC can be administered:

• Orally
• Intravenously

Both routes are effective when used appropriately.

Modern practice frequently uses IV NAC because it is easier to administer in patients with:

• Persistent vomiting
• Altered consciousness
• Severe poisoning
• Acute liver failure
• Inability to tolerate oral medication

The preferred route also depends on local protocols and product availability.

Old Oral Protocol

Historically, oral NAC was administered using a prolonged multi-dose regimen lasting several days.

Although effective, treatment duration is no longer viewed as an inflexible clock.

Modern practice increasingly emphasizes clinical and laboratory stopping criteria.

Modern IV NAC

IV NAC is now widely available and routinely used.

The older statement that an approved IV formulation was unavailable in the United States is obsolete.

Several IV administration protocols exist internationally.

Protocol choice varies by:

• Country
• Institution
• Poison center
• Clinical circumstances

Exact dosing should follow the current local protocol.

Do Not Give Oral NAC Formulation IV

The historical practice of administering an oral/inhalational NAC formulation intravenously is obsolete where approved IV NAC is available.

Only an appropriate formulation intended for parenteral use should be administered intravenously.

Duration of Treatment

A fixed protocol duration should not automatically determine when NAC stops.

At the expected end of treatment, reassess:

• Acetaminophen concentration
• AST/ALT
• INR
• Clinical condition

In severe poisoning also consider:

• Lactate
• Acid-base status
• Renal function
• Evidence of improving or worsening liver failure

When NAC Should Be Continued

Continue beyond the standard protocol when there is evidence such as:

• Persistent measurable acetaminophen
• Rising or significantly abnormal aminotransferases
• Worsening hepatic dysfunction
• Persistent clinically important coagulopathy
• Ongoing acute liver failure

Treatment is continued until appropriate stopping criteria are satisfied.

When NAC Can Usually Be Stopped

In general, discontinuation requires a reassuring combination of:

• Acetaminophen no longer clinically significant
• Improving hepatic injury
• Improving prognostic markers
• Clinically stable patient

Exact stopping criteria should follow current toxicology protocols.

IV NAC Reactions

IV NAC can cause non-IgE-mediated anaphylactoid reactions.

Possible manifestations include:

• Flushing
• Pruritus
• Urticaria
• Angioedema
• Wheezing
• Bronchospasm
• Hypotension

These reactions are related partly to histamine release and infusion conditions.

Anaphylactoid Reaction ≠ Permanent NAC Allergy

An important modern distinction:

A reaction to IV NAC does not automatically mean that NAC can never be given again.

Because NAC may be life-saving, management depends on reaction severity.

Treatment can include:

• Temporarily interrupting or slowing the infusion
• Antihistamine treatment for appropriate cutaneous reactions
• Standard emergency treatment for severe reactions
• Restarting NAC cautiously when clinically necessary after stabilization

Toxicology consultation is appropriate for severe reactions.

Risk of IV Reactions

Interestingly, anaphylactoid reactions are more frequent in patients with lower acetaminophen concentrations.

This may relate to acetaminophen itself reducing histamine-mediated reactions.

A history of asthma may also increase risk.

Oral NAC Adverse Effects

The most common problems are:

• Nausea
• Vomiting
• Unpleasant sulfur odor/taste

Antiemetic treatment may improve tolerance.

Medication-Error Risk

IV NAC has historically been associated with medication errors because treatment protocols may involve:

• Multiple infusion phases
• Different concentrations
• Weight-based calculations
• Different fluid volumes

Modern simplified protocols in some centers aim partly to reduce these errors.

Careful pharmacy preparation and protocol verification remain important.

Fluid Considerations

Standard IV preparation volumes may be excessive for:

• Small children
• Patients with fluid restriction
• Certain critically ill patients

Fluid volume should therefore be individualized while preserving the required NAC treatment.

Massive Acetaminophen Poisoning

Exceptionally large exposures may present early with:

• Profound metabolic acidosis
• Elevated lactate
• Altered mental status
• Mitochondrial dysfunction

This can occur before classic hepatic failure develops.

These cases require immediate toxicology consultation.

Selected severe cases may require intensified antidotal management and consideration of extracorporeal therapy.

Hemodialysis

Acetaminophen is dialyzable, but routine overdose does not require hemodialysis because NAC is highly effective.

Dialysis is reserved for selected extraordinary poisonings, particularly massive exposures associated with severe metabolic abnormalities and clinical deterioration.

Because dialysis can also remove NAC, antidotal therapy must be managed appropriately during extracorporeal treatment.

Activated Charcoal

Activated charcoal can reduce acetaminophen absorption when given to appropriately selected patients after a significant recent ingestion.

It should only be used when:

• Expected benefit is meaningful
• The substance is adsorbable
• Airway protection is adequate
• No contraindication exists

Modern evidence does not support automatically increasing the NAC dose simply because activated charcoal was administered.

Alcohol and Acetaminophen

The relationship between ethanol and acetaminophen toxicity is complex.

Acute ethanol exposure

Ethanol competes for CYP2E1 and can temporarily reduce NAPQI formation.

Chronic heavy alcohol use

Chronic alcohol exposure may increase CYP2E1 activity and is often associated with nutritional or glutathione-related vulnerabilities.

However:

Standard assessment and appropriate NAC treatment should not be withheld simply because a patient uses alcohol.

Pregnancy

The historical FDA Category B classification is obsolete.

Acetaminophen crosses the placenta, and maternal toxicity can threaten both mother and fetus.

NAC should be administered when indicated during pregnancy.

NAC itself also crosses the placenta.

Maternal stabilization and prevention of hepatic injury are central priorities.

Newborn Management

The older recommendation that every infant delivered to a mother receiving NAC automatically requires a complete independent NAC course is not a universal modern rule.

Neonatal management should instead depend on:

• Timing and severity of maternal poisoning
• Timing of delivery
• Neonatal acetaminophen exposure
• Neonatal laboratory findings
• Clinical condition

Neonatology and toxicology input is appropriate.

Other Proposed Uses

Older literature proposed NAC for several non-acetaminophen poisonings, including:

• Carbon tetrachloride
• Chloroform
• Amanita mushroom poisoning
• Monochloroacetic acid
• Selected chemotherapy toxicities

Evidence varies considerably.

NAC should not automatically be regarded as a specific antidote for these exposures.

Amanita Mushroom Poisoning

NAC has sometimes been incorporated into supportive regimens for severe amatoxin-associated hepatic injury.

However, it does not replace established management such as:

• Aggressive supportive care
• Specialist toxicology input
• Consideration of silibinin where available
• Early transplant-center involvement in progressive acute liver failure

Its precise independent benefit in amatoxin poisoning remains uncertain.

Non-Acetaminophen Acute Liver Failure

IV NAC has also been studied in some forms of acute liver failure unrelated to acetaminophen.

Potential benefit appears dependent on etiology and stage of illness.

This is a specialist hepatology/critical-care use rather than a general-purpose poisoning antidote.

Important Modernization of the Older Source

• NAC remains the specific antidotal therapy for acetaminophen poisoning.
• Its major early action is restoration of glutathione needed to detoxify NAPQI.
• NAC also provides benefit after hepatic injury has begun, so late presentation does not make treatment futile.
• The Rumack–Matthew nomogram applies only to an appropriately timed concentration after a single acute ingestion with a reasonably known time.
• The nomogram should not be applied to repeated supratherapeutic, staggered, or unknown-time exposures.
• Modified-release preparations and delayed absorption may require repeat acetaminophen concentrations.
• An undetectable acetaminophen level does not exclude late acetaminophen-induced liver injury.
• IV NAC is now widely available; historical use of oral/inhalational formulations intravenously is obsolete.
• Modern treatment duration is determined by clinical and laboratory stopping criteria, not simply completion of a fixed number of hours.
• NAC should continue when acetaminophen remains clinically significant or hepatic injury is ongoing.
• IV NAC reactions are usually anaphylactoid rather than classic IgE allergy and often do not permanently contraindicate further NAC.
• Severe acetaminophen-induced acute liver failure requires early transplant-center consideration.
• Hemodialysis is reserved for selected massive poisonings rather than routine overdose.
• NAC therapy remains appropriate during pregnancy when indicated.
• A newborn does not automatically require a complete NAC course solely because the mother received NAC.
• Historical pregnancy letter categories are obsolete.

Key Points

• Acetaminophen overdose → excess NAPQI → glutathione depletion → hepatocellular injury.
• NAC replenishes glutathione and detoxifies NAPQI.
• NAC works best when started early, especially within the first several hours, but remains beneficial in late toxicity and acute liver failure.
• Do not delay NAC in a high-risk exposure while waiting for delayed laboratory results.
• Use the Rumack–Matthew nomogram only for a single acute ingestion with a reliable time.
• Do not use the nomogram for unknown-time, staggered, or repeated supratherapeutic ingestion.
• Serial acetaminophen levels may be necessary when absorption is delayed.
• A low or undetectable acetaminophen concentration does not rule out late hepatic toxicity.
• Follow AST/ALT, INR, acetaminophen concentration, renal function, glucose, and clinical status as appropriate.
• Do not stop NAC merely because the standard protocol time has elapsed if hepatic injury or measurable acetaminophen persists.
• IV NAC can cause anaphylactoid reactions, but these often can be treated while preserving necessary antidotal therapy.
• Severe acute liver failure requires intensive supportive care and early consideration of liver-transplant evaluation.

Toxicology – Methylene Blue

Core Concept

Methylene blue is the principal antidotal treatment for clinically significant acquired methemoglobinemia.

It acts as an electron carrier that accelerates reduction of oxidized hemoglobin iron:

Methemoglobin (Fe³⁺) → functional hemoglobin (Fe²⁺)

Important limitations include G6PD deficiency, excessive dosing, recurrent methemoglobinemia, and its clinically important monoamine oxidase-A (MAO-A) inhibitory effect, which creates a risk of serotonin toxicity with serotonergic drugs.

⸻

Methemoglobin Formation

Normal hemoglobin contains iron in the ferrous (Fe²⁺) state, which can bind oxygen.

Oxidation converts it to the ferric (Fe³⁺) state:

Hb-Fe²⁺ → MetHb-Fe³⁺

Ferric heme cannot effectively bind oxygen.

Methemoglobin also increases the oxygen affinity of the remaining normal heme groups, impairing oxygen release to tissues.

The result is a form of functional anemia and tissue hypoxia.

⸻

Normal Methemoglobin Reduction

Small amounts of methemoglobin form continuously.

Normally, methemoglobin remains very low because erythrocytes continuously reduce Fe³⁺ back to Fe²⁺.

The dominant physiologic pathway is:

NADH-dependent cytochrome b5 reductase

This pathway handles most normal methemoglobin reduction.

A secondary NADPH-dependent pathway becomes therapeutically important when methylene blue is supplied.

⸻

How Methylene Blue Works

Within red blood cells, methylene blue accepts electrons through an NADPH-dependent pathway and is converted to leucomethylene blue.

Leucomethylene blue then acts as a reducing agent:

MetHb-Fe³⁺ → Hb-Fe²⁺

This restores hemoglobin capable of participating normally in oxygen transport.

⸻

Role of NADPH

NADPH is generated largely through the pentose phosphate pathway, which depends on adequate glucose-6-phosphate dehydrogenase (G6PD) activity.

Therefore:

G6PD deficiency → ↓ NADPH availability → impaired methylene-blue activity

This explains both reduced efficacy and some of the toxicity concerns in G6PD-deficient patients.

⸻

Common Causes of Acquired Methemoglobinemia

Important oxidizing agents include:

• Benzocaine
• Prilocaine
• Dapsone
• Nitrites and nitrates
• Aniline compounds
• Phenazopyridine
• Primaquine and related oxidant drugs
• Certain industrial chemicals

The clinical course depends on the agent, dose, duration, and presence of ongoing absorption or active metabolites.

⸻

Clinical Features

Increasing methemoglobinemia can cause:

• Cyanosis
• Headache
• Fatigue
• Dizziness
• Dyspnea
• Tachycardia
• Weakness

More severe tissue hypoxia may cause:

• Confusion
• Chest pain
• Metabolic acidosis
• Dysrhythmias
• Seizures
• Coma
• Cardiovascular collapse

Symptoms depend not only on the methemoglobin percentage but also on the patient’s oxygen-delivery reserve.

⸻

Why Some Patients Become Symptomatic Earlier

A patient may develop substantial symptoms at a comparatively lower methemoglobin fraction if they also have:

• Significant anemia
• Cardiopulmonary disease
• Sepsis or shock
• Concurrent carbon monoxide poisoning
• Other impairment of oxygen delivery

Therefore:

Treatment should be based on clinical toxicity plus the measured methemoglobin concentration, not a rigid percentage alone.

⸻

Cyanosis

Methemoglobinemia classically produces cyanosis that may persist despite supplemental oxygen.

The blood may appear:

• Dark
• Brown
• “Chocolate-colored”

However, blood appearance is only a clue and should not replace laboratory confirmation.

⸻

Pulse Oximetry

Standard pulse oximetry becomes unreliable in significant methemoglobinemia.

The displayed saturation often trends toward the mid-80% range regardless of the true arterial oxygen content.

Therefore:

SpO₂ does not accurately quantify methemoglobinemia.

⸻

PaO₂ Can Be Normal

An important diagnostic principle:

PaO₂ measures oxygen dissolved in plasma, not whether hemoglobin can carry that oxygen normally.

Thus, a patient can have:

• Significant cyanosis
• Low/refractory pulse-oximeter saturation
• Tissue hypoxia

while having a relatively normal or high PaO₂ after receiving oxygen.

⸻

Saturation Gap

A discrepancy may occur between:

• Oxygen saturation calculated from the blood gas
• Saturation measured by pulse oximetry

This “saturation gap” can suggest a dyshemoglobinemia.

However, definitive assessment requires co-oximetry.

⸻

Co-Oximetry

Co-oximetry directly distinguishes different hemoglobin species and is the preferred diagnostic method.

It can quantify:

• Oxyhemoglobin
• Deoxyhemoglobin
• Carboxyhemoglobin
• Methemoglobin

Serial measurements are useful after antidotal therapy and when recurrence is possible.

⸻

When Methylene Blue Is Considered

Treatment is particularly appropriate when methemoglobinemia produces clinically important manifestations such as:

• Dyspnea
• Neurologic abnormalities
• Chest pain
• Significant tissue hypoxia
• Hemodynamic instability

A high or rapidly increasing methemoglobin fraction may also warrant treatment even before major symptoms develop.

The threshold should be individualized according to oxygen-delivery reserve and clinical circumstances.

⸻

Initial Management

Management includes:

• Stop the oxidizing exposure
• Support airway and ventilation
• Administer supplemental oxygen
• Obtain co-oximetry
• Assess hemodynamic and neurologic status
• Treat clinically important methemoglobinemia with methylene blue when appropriate

Oxygen alone does not rapidly convert Fe³⁺ back to Fe²⁺ but maximizes oxygen availability to the remaining functional hemoglobin and dissolved plasma compartment.

⸻

Expected Response

When methylene blue is effective, improvement is generally relatively rapid.

Expected findings include:

• Improved cyanosis
• Improved symptoms
• Falling methemoglobin concentration

Failure to improve should prompt reassessment rather than unlimited repeat administration.

⸻

Recurrent Methemoglobinemia

Methemoglobinemia can recur after an initial response if:

• The oxidant remains in the gastrointestinal tract
• The causative drug has a long half-life
• Active metabolites continue to circulate
• Enterohepatic recirculation occurs

Dapsone is a classic cause of prolonged or recurrent methemoglobinemia.

Serial co-oximetry may therefore be required.

⸻

Dapsone Poisoning

Dapsone can cause:

• Methemoglobinemia
• Hemolysis
• Recurrent methemoglobin formation

Its metabolites can persist and undergo enterohepatic recirculation.

Selected substantial ingestions may benefit from multiple-dose activated charcoal when appropriate and safe because charcoal can enhance elimination of dapsone and its metabolites.

⸻

G6PD Deficiency

G6PD deficiency is an important limitation.

Because methylene blue requires NADPH:

↓ G6PD activity → ↓ NADPH → reduced antidotal effect

In addition, methylene blue itself has oxidant properties and can worsen hemolysis, particularly at higher exposure.

Thus, methylene blue may be ineffective or harmful in substantial G6PD deficiency.

⸻

G6PD Status May Be Unknown

In an emergency, the patient’s G6PD status may not be immediately available.

Management therefore depends on:

• Severity of methemoglobinemia
• Clinical evidence of hemolysis
• Known history
• Likelihood of G6PD deficiency
• Availability of alternative treatment

Severe cases warrant urgent toxicology and hematology input.

⸻

Paradoxical Methemoglobinemia

Methylene blue is itself an oxidizing compound.

At excessive cumulative exposure:

Methylene blue can worsen rather than improve methemoglobinemia.

Therefore, repeated administration without an appropriate response should trigger reassessment rather than escalating indefinitely.

⸻

Serotonin Toxicity – Major Modern Interaction

The older statement that methylene blue has “no known drug interactions” is importantly outdated.

Methylene blue is a potent inhibitor of monoamine oxidase-A (MAO-A).

It can therefore impair serotonin metabolism.

When combined with serotonergic medications, it can precipitate serotonin syndrome.

⸻

Important Serotonergic Drugs

Risk is particularly relevant with drugs such as:

• SSRIs
• SNRIs
• MAO inhibitors
• Clomipramine and other strongly serotonergic antidepressants
• Certain other serotonergic medications

Medication history should be reviewed whenever circumstances permit.

⸻

Serotonin Syndrome

Features can include:

• Agitation
• Tremor
• Hyperreflexia
• Inducible or spontaneous clonus
• Diaphoresis
• Tachycardia
• Hyperthermia
• Diarrhea

Severe cases may develop:

• Marked hyperthermia
• Severe rigidity
• Rhabdomyolysis
• Metabolic acidosis
• Organ failure

Clonus and hyperreflexia are particularly useful diagnostic clues.

⸻

Do Not Automatically Withhold Life-Saving Therapy

The serotonergic interaction is important, but a patient with life-threatening methemoglobinemia may also urgently require restoration of oxygen-carrying capacity.

The risks must therefore be balanced according to severity, with specialist input when available.

⸻

Sulfhemoglobinemia

Sulfhemoglobinemia can resemble methemoglobinemia clinically.

Patients may have:

• Persistent cyanosis
• Abnormal pulse oximetry
• Dyshemoglobinemia findings

However:

Sulfhemoglobin does not respond to methylene blue.

Recognition is important when apparent methemoglobinemia fails to respond as expected.

⸻

Congenital Methemoglobinemia

Some patients have congenital disorders of methemoglobin reduction, including deficiency of cytochrome b5 reductase.

The management of congenital disease differs from typical acute oxidant poisoning.

Chronic cyanosis without acute illness should therefore prompt consideration of hereditary causes.

⸻

Alternative and Rescue Treatments

When methylene blue is ineffective, contraindicated, or hazardous, management may include specialist-directed alternatives such as:

• High-concentration oxygen
• Removal of the causative oxidant
• Ascorbic acid in selected situations
• Blood transfusion or exchange transfusion in exceptional severe cases
• Hyperbaric oxygen as an uncommon rescue strategy when severe tissue hypoxia cannot otherwise be corrected

These approaches are not equivalent to methylene blue in routine acquired methemoglobinemia.

⸻

Ascorbic Acid

Vitamin C is a reducing agent and can lower methemoglobin through nonenzymatic mechanisms.

Its action is generally much slower than methylene blue.

It is therefore more useful in selected circumstances, such as when methylene blue cannot be used, rather than as routine first-line treatment for severe acute toxicity.

⸻

Hemolysis

Methylene blue can contribute to oxidative red-cell injury.

Risk is especially important with:

• G6PD deficiency
• Repeated/high exposure
• Other oxidizing agents

Monitor for evidence such as:

• Falling hemoglobin
• Jaundice
• Elevated bilirubin
• Elevated LDH
• Reduced haptoglobin
• Hemoglobinuria

when clinically indicated.

⸻

Other Adverse Effects

Possible adverse effects include:

• Nausea
• Vomiting
• Headache
• Dizziness
• Sweating
• Chest discomfort
• Blood-pressure changes
• Dysrhythmias
• Confusion

Extravasation can cause local tissue injury.

⸻

Blue-Green Discoloration

Methylene blue can discolor:

• Urine
• Stool
• Skin or mucosal secretions

Blue or green urine after treatment is generally expected and does not by itself indicate worsening toxicity.

⸻

Laboratory Interference

Because methylene blue is an intensely colored dye, it can interfere with some optical laboratory and monitoring methods.

Results that appear inconsistent with the patient’s clinical state should therefore be interpreted cautiously after administration.

⸻

Pregnancy

The historical FDA Category C system is obsolete.

Management should be based on:

• Severity of maternal methemoglobinemia
• Degree of tissue hypoxia
• Gestational circumstances
• Risks of treatment versus untreated hypoxia

Severe maternal hypoxia itself poses substantial fetal risk.

Specialist consultation is appropriate when significant methemoglobinemia occurs during pregnancy.

⸻

Monitoring

Important monitoring includes:

• Airway and respiratory status
• Continuous pulse oximetry, recognizing its limitations
• Co-oximetry
• Serial methemoglobin concentrations
• ECG
• Blood pressure
• Neurologic status
• Acid-base status in severe poisoning
• Hemoglobin and markers of hemolysis when indicated

Patients with long-acting oxidants require monitoring for recurrence.

⸻

Important Modernization of the Older Source

• Methemoglobin contains ferric Fe³⁺, whereas functional hemoglobin requires ferrous Fe²⁺.
• The major normal methemoglobin-reduction pathway is NADH-dependent cytochrome b5 reductase.
• Methylene blue uses an NADPH-dependent auxiliary pathway to accelerate reduction of methemoglobin.
• Clinical treatment should not rely on a rigid methemoglobin percentage alone.
• Patients with anemia or cardiopulmonary disease may become symptomatic at substantially lower levels.
• Standard pulse oximetry is unreliable; co-oximetry is the diagnostic standard.
• PaO₂ may remain normal despite severe methemoglobinemia.
• G6PD deficiency can reduce methylene-blue effectiveness and increase the risk of hemolysis.
• Excessive methylene blue can paradoxically worsen methemoglobinemia.
• Methylene blue is an MAO-A inhibitor and can precipitate serotonin syndrome when combined with serotonergic drugs.
• The older claim that methylene blue has no significant drug interactions is therefore incorrect.
• Dapsone can cause prolonged and recurrent methemoglobinemia.
• Sulfhemoglobinemia generally does not respond to methylene blue.
• Ascorbic acid is a slower alternative in selected circumstances.
• Hyperbaric oxygen and exchange transfusion are exceptional rescue strategies rather than routine therapy.
• Historical FDA pregnancy letter categories are obsolete.
• Exact emergency dosing should follow current toxicology and institutional protocols.

Key Points

• Methylene blue is the principal antidote for clinically significant acquired methemoglobinemia.
• It facilitates conversion of Fe³⁺ methemoglobin back to Fe²⁺ functional hemoglobin.
• Methemoglobinemia causes functional anemia and impaired tissue oxygen delivery.
• Persistent cyanosis despite oxygen, chocolate-brown blood, and pulse oximetry near the mid-80s are useful clues.
• A normal PaO₂ does not exclude methemoglobinemia.
• Confirm and follow the condition with co-oximetry.
• Treatment depends on symptoms, methemoglobin burden, and the patient’s underlying oxygen-delivery reserve.
• G6PD deficiency can make methylene blue less effective and increase hemolysis risk.
• Excessive methylene blue can itself produce methemoglobinemia.
• Methylene blue inhibits MAO-A and can precipitate serotonin toxicity with serotonergic medications.
• Dapsone poisoning may produce recurrent methemoglobinemia requiring prolonged monitoring.
• Failure to respond should prompt consideration of G6PD-related limitations, ongoing oxidant exposure, congenital disease, or sulfhemoglobinemia.

Toxicology – Magnesium Sulfate

Core Concept

Magnesium sulfate is an important electrolyte therapy and antiarrhythmic agent.

Its major toxicologic uses include:

• Torsades de pointes
• Correction of clinically important hypomagnesemia
• Adjunctive management of selected hydrofluoric acid/hydrogen fluoride (HF) toxicity

Its most established emergency antiarrhythmic role is treatment of torsades associated with acquired QT prolongation.

Magnesium Physiology

Magnesium is predominantly an intracellular cation involved in:

• Membrane stability
• Potassium regulation
• Calcium transport
• ATP-dependent reactions
• Neuromuscular transmission
• Cardiac electrophysiology

Abnormal magnesium concentrations can therefore affect both the heart and neuromuscular system.

Torsades de Pointes

Torsades de pointes is a form of polymorphic ventricular tachycardia occurring in the setting of prolonged ventricular repolarization, usually reflected by QT prolongation.

Typical ECG appearance:

• Rapid polymorphic ventricular rhythm
• QRS complexes appear to rotate around the baseline
• Usually associated with prolonged QT before onset

Torsades can spontaneously terminate, recur repeatedly, or deteriorate into ventricular fibrillation.

Why QT Prolongation Matters

Prolonged repolarization facilitates development of:

Early afterdepolarizations → triggered ventricular activity → torsades

Risk is increased by factors such as:

• QT-prolonging medications
• Hypokalemia
• Hypomagnesemia
• Bradycardia
• Congenital long-QT syndromes
• Drug interactions that increase concentrations of QT-prolonging agents

How Magnesium Helps Torsades

The older description that magnesium works mainly by prolonging AV nodal or sinoatrial conduction is incomplete.

Its clinically important anti-torsades effect is more closely related to:

• Suppression of early afterdepolarizations
• Stabilization of myocardial electrical activity
• Modulation of calcium-dependent currents

Importantly:

Magnesium can terminate or suppress torsades even when the serum magnesium concentration is initially normal.

Toxicologic Causes of QT Prolongation

Drug-induced QT prolongation can occur with substances such as:

• Certain antiarrhythmics
• Some antipsychotics
• Some antidepressants
• Methadone
• Certain antihistamines
• Selected antimicrobials
• Other QT-prolonging xenobiotics

Risk becomes greater when multiple QT-prolonging factors coexist.

Management of Torsades

Treatment priorities include:

• Stop the causative QT-prolonging drug
• Correct hypokalemia
• Correct hypomagnesemia
• Administer magnesium for torsades
• Correct other relevant metabolic abnormalities
• Continuous ECG monitoring

Potassium is commonly maintained toward the upper part of the normal range in acquired long-QT states.

Unstable Torsades

If torsades causes:

• Severe hypotension
• Loss of consciousness
• Shock
• Pulselessness

then immediate electrical treatment takes priority.

Magnesium should not delay defibrillation of an unstable or pulseless ventricular dysrhythmia.

Recurrent Torsades

Some patients continue to have recurrent episodes despite magnesium and correction of electrolytes.

In acquired long-QT torsades associated with bradycardia or pauses, increasing the heart rate may shorten repolarization and reduce recurrence.

Selected approaches include:

• Temporary overdrive pacing
• Pharmacologic chronotropic therapy in appropriate acquired cases

The underlying cause must still be corrected.

Congenital vs Acquired Long-QT Syndrome

Treatment should distinguish between:

• Acquired drug-induced long-QT syndrome
• Congenital long-QT syndrome

A strategy appropriate for pause-dependent acquired torsades may not be appropriate for every congenital long-QT subtype.

Cardiology input is appropriate for recurrent or unexplained torsades.

Magnesium Is Not a Universal Ventricular Antiarrhythmic

Magnesium should not automatically be given for every ventricular tachycardia.

Its strongest indications include:

• Torsades de pointes
• Ventricular dysrhythmias associated with significant hypomagnesemia

Other toxicologic ventricular dysrhythmias require mechanism-specific treatment.

For example, significant sodium-channel blockade may respond to sodium bicarbonate, not magnesium alone.

Hydrofluoric Acid / Hydrogen Fluoride Toxicity

HF exposure is unusual because fluoride can penetrate tissues deeply and bind physiologically important cations.

Fluoride avidly interacts with:

• Calcium
• Magnesium

Severe poisoning can therefore produce profound electrolyte abnormalities and life-threatening cardiotoxicity.

Systemic HF Toxicity

Significant HF exposure can cause:

• Hypocalcemia
• Hypomagnesemia
• Hyperkalemia
• QT abnormalities
• Ventricular dysrhythmias
• Severe pain
• Tissue injury
• Cardiovascular collapse

Systemic deterioration can sometimes be rapid.

Role of Magnesium in HF Poisoning

Magnesium can bind fluoride and may help correct fluoride-associated magnesium depletion.

However:

Calcium therapy remains central to clinically important HF toxicity.

Magnesium should be considered an adjunct, particularly when hypomagnesemia or ventricular electrical instability is present.

It should not replace appropriate calcium treatment.

Dermal HF Exposure

Immediate priorities include:

• Rapid removal from exposure
• Removal of contaminated clothing
• Copious water irrigation
• Early treatment with topical calcium gluconate when appropriate
• Assessment for systemic toxicity in significant exposures

Older literature described local magnesium preparations, but calcium gluconate is substantially better established.

Advanced local or invasive treatment should be performed only by experienced clinicians.

HF Ingestion

Ingestion of concentrated HF can cause catastrophic:

• Gastrointestinal injury
• Hypocalcemia
• Hypomagnesemia
• Hyperkalemia
• Ventricular dysrhythmias
• Shock

This is a medical emergency requiring immediate poison-center/medical-toxicology involvement and aggressive supportive care.

Management is driven by ECG findings, ionized calcium, magnesium, potassium, acid-base status, and overall clinical condition rather than routine prophylactic magnesium administration.

Ionized Calcium

In serious HF toxicity, ionized calcium is particularly useful because it directly reflects the physiologically active calcium fraction.

Serial measurements may be necessary because electrolyte abnormalities can evolve rapidly.

Magnesium Toxicity

Excessive magnesium produces progressive neuromuscular and cardiovascular depression.

Possible manifestations include:

• Nausea
• Flushing
• Lethargy
• Muscle weakness
• Reduced deep-tendon reflexes
• Hypotension
• Bradycardia
• Respiratory depression
• Conduction abnormalities
• Coma
• Cardiac arrest in extreme toxicity

Loss of Deep-Tendon Reflexes

Diminishing reflexes are a useful bedside clue to clinically important hypermagnesemia.

However, the older statement that clinical examination should be used instead of serum magnesium concentrations is too strong.

Modern management uses both:

• Clinical examination
• Respiratory status
• ECG/hemodynamics
• Renal function
• Serum magnesium when relevant

No single parameter should be used in isolation.

Respiratory Depression

Increasing magnesium concentrations impair neuromuscular transmission.

Progressive toxicity can produce:

Weakness → hyporeflexia → respiratory muscle weakness → respiratory failure

Airway and ventilatory support may be required in severe toxicity.

Renal Function

Magnesium is predominantly eliminated through the kidneys.

Therefore:

Renal impairment → reduced magnesium clearance → increased risk of accumulation

Particular caution is required with:

• Acute kidney injury
• Advanced chronic kidney disease
• Oliguria
• Anuria

Renal function and urine output should be monitored during substantial magnesium therapy.

Treatment of Severe Hypermagnesemia

Management includes:

• Stop exogenous magnesium
• Support airway and ventilation
• Continuous cardiac monitoring
• Correct hemodynamic instability

IV calcium can temporarily antagonize the cardiac and neuromuscular effects of excess magnesium.

For severe symptomatic hypermagnesemia with impaired renal clearance:

Hemodialysis can rapidly remove magnesium.

Neuromuscular Blocking Agents

Magnesium decreases acetylcholine release and reduces neuromuscular excitability.

It can therefore potentiate the effects of:

• Nondepolarizing neuromuscular blockers
• Other agents that impair neuromuscular transmission

This can increase weakness and respiratory depression.

Aminoglycosides

Aminoglycosides can themselves interfere with neuromuscular transmission.

Combined exposure with substantial magnesium can therefore increase the risk of:

• Weakness
• Neuromuscular blockade
• Respiratory failure

Clinical monitoring is important when these effects may overlap.

Pregnancy

The historical FDA Category B system is obsolete.

Magnesium sulfate remains an established medication in obstetric care, particularly for selected conditions such as:

• Prevention/treatment of eclamptic seizures
• Fetal neuroprotection in specific circumstances

However, prolonged or excessive exposure can produce maternal and neonatal toxicity.

Pregnancy itself is not a contraindication when magnesium is clinically indicated.

ECG Monitoring

In toxicologic situations requiring substantial magnesium therapy, monitor for:

• QT changes
• PR prolongation
• QRS changes with significant toxicity
• Bradycardia
• AV conduction abnormalities
• Ventricular dysrhythmias

The ECG should always be interpreted together with the underlying poisoning.

Important Modernization of the Older Source

• Magnesium sulfate is a first-line pharmacologic treatment for torsades de pointes.
• Torsades is polymorphic VT associated with prolonged ventricular repolarization/QT prolongation.
• Magnesium’s anti-torsades effect is primarily related to suppression of early afterdepolarizations and stabilization of myocardial electrophysiology, rather than simply prolongation of AV nodal conduction.
• Magnesium can be effective in torsades even when the measured serum magnesium is normal.
• Electrical treatment takes priority in unstable or pulseless ventricular dysrhythmias.
• Correct hypokalemia and remove QT-prolonging causes simultaneously.
• Recurrent pause-dependent acquired torsades may require an increase in heart rate through specialist-directed therapy.
• Magnesium is not a universal treatment for all ventricular tachycardias.
• In HF poisoning, calcium remains the central cation-replacement/fluoride-binding therapy; magnesium is an adjunct.
• Routine prophylactic magnesium after HF ingestion should not be based simply on the history of a “large ingestion”; treatment should be individualized using ECG, ionized calcium, magnesium, potassium, and clinical status.
• Calcium gluconate is better established than topical/local magnesium for dermal HF injury.
• Renal impairment substantially increases the risk of magnesium accumulation.
• Severe hypermagnesemia can produce hyporeflexia, respiratory depression, hypotension, bradycardia, and cardiac arrest.
• IV calcium can temporarily antagonize serious magnesium toxicity.
• Hemodialysis is effective for severe hypermagnesemia when renal elimination is inadequate.
• Both bedside examination and serum magnesium measurements can be useful; neither should automatically replace the other.
• Historical pregnancy letter categories are obsolete.
• Exact emergency dosing should follow current resuscitation, poison-center, and medical-toxicology protocols.

Key Points

• Magnesium sulfate is an important treatment for torsades de pointes.
• It suppresses the early afterdepolarizations that contribute to torsades.
• It may work even when serum magnesium is normal.
• Defibrillation/cardioversion should not be delayed when the ventricular dysrhythmia is unstable.
• Correct potassium, magnesium, and other reversible QT-prolonging factors.
• Magnesium is not the appropriate antidote for every form of ventricular tachycardia.
• HF toxicity can produce dangerous hypocalcemia, hypomagnesemia, hyperkalemia, QT abnormalities, and ventricular dysrhythmias.
• Calcium therapy is central in serious HF toxicity; magnesium is adjunctive.
• Magnesium is renally eliminated, so renal failure markedly increases toxicity risk.
• Progressive hypermagnesemia causes loss of reflexes, muscle weakness, respiratory depression, hypotension, and cardiac conduction abnormalities.
• Severe symptomatic magnesium toxicity may require IV calcium, ventilatory support, and dialysis when renal clearance is inadequate.

Toxicology – Syrup of Ipecac

Core Concept

Syrup of ipecac is an oral emetic that was historically used to induce vomiting after poisoning.

It contains the alkaloids:

• Emetine
• Cephaeline

Although once widely kept in homes and used for gastrointestinal decontamination, ipecac has essentially no role in modern routine poisoning management.

The central modern principle is:

Do not induce vomiting after a poisoning unless specifically directed in an exceptional circumstance by a medical toxicologist or poison center.

⸻

Mechanism of Action

Ipecac produces vomiting through both central and peripheral mechanisms.

Central effect

Cephaeline and related alkaloids stimulate pathways involved in the vomiting response.

Gastrointestinal effect

Emetine and cephaeline irritate the gastrointestinal tract and stimulate visceral afferent pathways.

The result is:

Nausea → retching → repeated vomiting

Vomiting can persist well beyond the initial episode.

⸻

Historical Rationale

Ipecac was originally intended to remove poison from the stomach before substantial absorption occurred.

The theory was:

Ingestion → induce vomiting → expel stomach contents → reduce systemic absorption

However, producing vomiting does not reliably empty the stomach.

Clinical studies failed to demonstrate that routine ipecac administration improves meaningful outcomes after poisoning.

⸻

Why Ipecac Was Abandoned

Routine use declined because:

• It does not reliably remove enough toxin to improve outcomes.
• Vomiting may be delayed.
• Poison absorption continues while waiting for emesis.
• Vomiting can persist.
• Aspiration can occur.
• It may delay activated charcoal or antidotes.
• It can interfere with transport and emergency evaluation.
• Patients may deteriorate neurologically while vomiting.

Therefore:

Routine home, prehospital, emergency-department, and pediatric use is no longer recommended.

⸻

Prehospital Poisoning

The older recommendation to administer ipecac when a patient is far from a healthcare facility is obsolete.

Modern priorities are:

• Contact an appropriate poison-information service or emergency service
• Assess airway, breathing, and circulation
• Identify the substance, amount, and time of exposure
• Follow substance-specific advice
• Arrange appropriate medical assessment when indicated

Distance from a hospital does not by itself justify induced vomiting.

⸻

Pediatric Poisoning

Ipecac was once especially common in pediatric poisonings.

Modern practice specifically moved away from this approach.

Parents and caregivers should not routinely induce vomiting in a child after ingestion.

Children can deteriorate unexpectedly, and vomiting increases the risk of aspiration.

⸻

Caustic Ingestion

Ipecac must not be used after ingestion of corrosive substances such as strong acids or alkalis.

Vomiting would re-expose the:

• Esophagus
• Pharynx
• Mouth
• Airway

to the corrosive material.

This can worsen tissue injury and increase aspiration risk.

⸻

Hydrocarbon Ingestion

Vomiting is particularly undesirable after many hydrocarbon exposures.

Examples include products such as:

• Kerosene
• Gasoline
• Lamp oil
• Some petroleum distillates

The major danger is often pulmonary aspiration, rather than systemic absorption from the gastrointestinal tract.

Inducing vomiting can markedly increase the opportunity for hydrocarbon to enter the lungs.

⸻

Sharp Objects

Vomiting should not be induced after ingestion of:

• Sharp objects
• Jagged foreign bodies
• Other material capable of mechanically injuring the gastrointestinal tract

Forced retrograde movement can cause additional injury.

⸻

Patient With Impaired Consciousness

Ipecac should not be administered when airway protection is impaired.

This includes patients with:

• Significant sedation
• Coma
• Severe confusion
• Loss of protective airway reflexes

Vomiting in these circumstances creates substantial aspiration risk.

⸻

Expected Neurologic Deterioration

Ipecac is also dangerous when the ingested substance may soon produce:

• Seizures
• Rapid sedation
• Coma
• Severe agitation

A patient who is initially awake may lose airway protection while vomiting.

This is one reason poisoning management cannot be based solely on the patient’s initial appearance.

⸻

Persistent Vomiting

The most common adverse effect is prolonged nausea and vomiting.

Consequences can include:

• Dehydration
• Electrolyte abnormalities
• Difficulty administering oral treatments
• Delayed medical care
• Aspiration

Persistent vomiting can also confuse assessment because it may be attributed incorrectly to the original poison.

⸻

Aspiration

Aspiration is one of the most clinically important complications.

Vomited material can enter the respiratory tract and cause:

• Chemical pneumonitis
• Airway obstruction
• Hypoxemia
• Respiratory failure

Risk is particularly high with hydrocarbons and impaired consciousness.

⸻

Mechanical Complications of Forceful Vomiting

Repeated forceful emesis can occasionally cause:

• Mallory-Weiss mucosal tears
• Gastrointestinal bleeding
• Esophageal injury
• Pneumomediastinum
• Rare serious thoracic complications

These risks further weaken any rationale for routine induced vomiting.

⸻

Cardiovascular Effects

Forceful vomiting can produce substantial vagal stimulation.

Possible consequences include:

• Bradycardia
• Presyncope
• Syncope

More importantly, chronic exposure to ipecac can produce direct cardiotoxicity from emetine.

⸻

Chronic Ipecac Abuse

Repeated or prolonged ipecac use can cause serious systemic toxicity.

Emetine accumulates in tissues and can injure:

• Cardiac muscle
• Skeletal muscle

Potential manifestations include:

• Progressive weakness
• Myopathy
• Cardiomyopathy
• Dysrhythmias
• Heart failure
• Electrolyte abnormalities

Severe chronic toxicity can be fatal.

⸻

Eating Disorders and Ipecac

Historically, chronic ipecac misuse occurred in some patients attempting to induce vomiting repeatedly.

This is medically dangerous because emetine toxicity can persist even after use stops.

Unexplained:

• Proximal muscle weakness
• Cardiomyopathy
• Dysrhythmias
• Persistent gastrointestinal symptoms

may warrant consideration of chronic emetine exposure when clinically appropriate.

⸻

Activated Charcoal

Ipecac should not be given simply as preparation for activated charcoal.

Vomiting can:

• Delay charcoal administration
• Cause charcoal to be vomited
• Increase aspiration risk

Activated charcoal itself is now used only for selected adsorbable poisonings when anticipated benefit outweighs risk.

⸻

Antidote Administration

Induced vomiting may interfere with orally administered therapies.

For example, repeated vomiting can prevent reliable delivery or retention of an oral antidote or other necessary medication.

Modern management prioritizes effective, toxin-specific treatment rather than attempting routine emesis first.

⸻

Ipecac vs Gastric Lavage

The older source suggests choosing gastric lavage instead of ipecac in many circumstances.

This also requires modernization:

Neither ipecac nor gastric lavage is routinely recommended for poisoned patients.

Gastric lavage now has, at most, a very narrow role in exceptional potentially life-threatening exposures when performed early by experienced clinicians with appropriate airway protection.

It is not the routine replacement for ipecac.

⸻

Large Tablets and Plant Material

Older practice suggested ipecac for large tablets or plant material that might not pass through a lavage tube.

This is no longer a routine indication.

Management instead depends on:

• Specific toxin
• Toxicity of the exposure
• Time since ingestion
• Formulation
• Gastrointestinal function
• Imaging when relevant
• Availability of more appropriate decontamination or elimination strategies

⸻

Whole-Bowel Irrigation

For selected situations involving material poorly managed by activated charcoal, whole-bowel irrigation may occasionally be considered.

Examples can include selected:

• Sustained-release preparations
• Enteric-coated drugs
• Iron or certain other poorly adsorbed substances
• Drug packets

This is a specialist-directed intervention and does not create a modern role for ipecac.

⸻

Pregnancy

The historical FDA pregnancy letter-category system is obsolete.

More importantly, because ipecac itself has essentially no routine therapeutic role in poisoning, pregnancy rarely creates a situation in which its potential benefits need to be weighed.

Management should instead use appropriate substance-specific supportive and antidotal treatment.

⸻

Ipecac Toxicity

If ipecac itself has been consumed excessively, management is primarily supportive.

Evaluation may include:

• Hydration status
• Electrolytes
• ECG
• Cardiac function when chronic exposure is suspected
• Assessment for aspiration
• Evaluation of muscle weakness

There is no specific antidote for emetine toxicity.

⸻

Modern Gastrointestinal Decontamination Principle

Poison management has shifted away from:

“Remove everything from the stomach.”

Instead, clinicians ask:

• What substance was ingested?
• How toxic is the amount?
• Has it already been absorbed?
• Will decontamination meaningfully change outcome?
• Does the intervention create more risk than benefit?

For most poisonings, supportive care and specific antidotes are more important than gastric emptying.

⸻

Important Modernization of the Older Source

• Syrup of ipecac is an emetic containing emetine and cephaeline.
• It was historically used to induce vomiting after poisoning.
• Routine ipecac administration is obsolete.
• It should not routinely be kept or used as a home poisoning treatment.
• Being far from a healthcare facility is no longer an indication for ipecac.
• Small patient size is not an indication.
• Large tablets or plant material do not create a routine indication.
• Ipecac has not been shown to improve clinically meaningful outcomes in poisoning.
• It can delay activated charcoal, antidotes, transportation, and definitive medical care.
• It is particularly dangerous after caustic or hydrocarbon ingestion.
• It should not be used when consciousness may deteriorate or seizures may occur.
• Persistent vomiting and aspiration are important complications.
• Chronic ipecac exposure can cause emetine-associated myopathy and cardiomyopathy.
• Gastric lavage is not the routine modern alternative to ipecac; lavage itself has only rare, highly selected indications.
• Historical pregnancy categories are obsolete.
• Routine dosing instructions for inducing emesis are no longer clinically appropriate.

⸻

Key Points

• Ipecac induces vomiting through central and gastrointestinal actions of emetine and cephaeline.
• It was once widely used for gastrointestinal decontamination.
• It is no longer recommended routinely for poisoning.
• Clinical benefit has not been demonstrated, while important harms are possible.
• Never routinely induce vomiting after a poisoning.
• Caustic ingestion is especially unsuitable because vomiting can cause repeat corrosive injury.
• Hydrocarbon ingestion is especially unsuitable because vomiting increases aspiration risk.
• Ipecac is unsafe when consciousness may deteriorate or seizures are possible.
• Persistent vomiting can cause dehydration, aspiration, and delays in effective therapy.
• Chronic ipecac misuse can produce serious cardiomyopathy and skeletal myopathy.
• Gastric lavage has not replaced ipecac as routine treatment; it too is reserved for exceptional situations.
• Modern poisoning management emphasizes supportive care, selected activated charcoal, specific antidotes, and toxin-directed treatment rather than induced emesis.

Toxicology – Hyperbaric Oxygen Therapy (HBOT)

Core Concept

Hyperbaric oxygen therapy (HBOT) delivers nearly 100% oxygen while the patient is exposed to pressure greater than normal atmospheric pressure inside a hyperbaric chamber.

In toxicology, its principal established role is in selected patients with carbon monoxide (CO) poisoning.

Older literature proposed HBOT for several other poisonings, but many of these indications have weak or uncertain evidence and are not routine modern practice.

Basic Principle

At normal atmospheric pressure, most oxygen is transported bound to hemoglobin, with only a small amount physically dissolved in plasma.

Increasing ambient pressure while breathing nearly 100% oxygen markedly increases the amount of dissolved plasma oxygen.

This can temporarily improve oxygen delivery even when normal hemoglobin-mediated oxygen transport is impaired.

Hyperbaric vs Normobaric Oxygen

Normobaric oxygen

High-concentration oxygen administered at approximately normal atmospheric pressure.

This is the immediate treatment for suspected significant CO poisoning.

Hyperbaric oxygen

High-concentration oxygen delivered at elevated ambient pressure.

HBOT provides:

• Much higher dissolved plasma oxygen
• More rapid CO elimination
• Very high tissue oxygen tensions

However, the need for HBOT depends on the clinical situation rather than simply the presence of CO exposure.

Hyperbaric Chambers

Two broad designs are used.

Monoplace chamber

• Usually accommodates one patient
• Entire chamber may be pressurized with oxygen
• Direct physical access to the patient during treatment is limited

Multiplace chamber

• Accommodates multiple people
• Chamber is usually pressurized with air
• Patients receive oxygen through masks, hoods, or airway systems
• Trained clinical personnel may remain inside with critically ill patients

The available chamber type can influence whether an unstable patient can safely undergo treatment.

Carbon Monoxide Poisoning

CO causes toxicity through several mechanisms.

It binds hemoglobin with high affinity:

CO + hemoglobin → carboxyhemoglobin (COHb)

This:

• Reduces oxygen-carrying capacity
• Interferes with oxygen unloading to tissues

But CO toxicity is more complex than COHb formation alone.

Cellular Effects of Carbon Monoxide

CO also interacts with intracellular proteins such as:

• Myoglobin
• Mitochondrial cytochromes

Consequences may include:

• Cellular hypoxia
• Oxidative stress
• Mitochondrial dysfunction
• Inflammatory injury
• Lipid peroxidation
• Neurologic and myocardial injury

This helps explain why the COHb concentration does not perfectly predict clinical severity.

How Oxygen Accelerates CO Elimination

CO dissociates from hemoglobin over time.

Increasing inspired oxygen accelerates this process.

Therefore:

Room air → slower CO elimination

100% normobaric oxygen → faster elimination

Hyperbaric oxygen → even faster elimination

HBOT also substantially increases dissolved oxygen available to tissues.

Possible Additional Effects of HBOT

Beyond accelerating CO elimination, HBOT may influence secondary injury pathways associated with CO poisoning.

Proposed effects include reduction of:

• Leukocyte-mediated injury
• Oxidative stress
• Lipid peroxidation
• Post-hypoxic inflammatory processes

These mechanisms have been proposed as explanations for potential neurologic benefit.

Immediate Management of Suspected CO Poisoning

Do not delay oxygen while deciding whether HBOT is appropriate.

Initial management includes:

• Removal from the exposure
• High-concentration oxygen
• Airway and ventilatory support when necessary
• ECG
• Neurologic assessment
• Evaluation for myocardial injury when appropriate
• COHb measurement by co-oximetry
• Assessment for associated smoke-inhalation injuries

HBOT consultation can occur simultaneously.

Pulse Oximetry Limitation

Standard pulse oximetry can appear normal or reassuring in significant CO poisoning.

Conventional pulse oximeters cannot reliably distinguish:

• Oxyhemoglobin
• Carboxyhemoglobin

Therefore:

A normal SpO₂ does not exclude CO poisoning.

Co-oximetry is required to measure COHb accurately.

COHb Concentration

COHb helps confirm exposure but should not be interpreted as a direct toxicity score.

The measured concentration can be affected by:

• Time since exposure
• Duration of oxygen therapy before sampling
• Exposure intensity
• Smoking status
• Ventilation

A patient can therefore have serious neurologic or cardiac toxicity despite a relatively modest COHb concentration measured later.

When HBOT Is Considered for CO Poisoning

There is no universally accepted single threshold that determines treatment.

Urgent hyperbaric consultation is particularly reasonable when significant CO poisoning is accompanied by features such as:

• Loss of consciousness
• Persistent or substantial neurologic abnormalities
• Severe altered mental status
• Seizures
• Significant myocardial ischemia or cardiac injury
• Hemodynamic instability
• Severe metabolic acidosis
• Substantial COHb elevation in the appropriate clinical context
• Pregnancy with clinically significant poisoning

The entire clinical picture matters.

Do Not Use COHb Alone

Older recommendations often relied heavily on fixed COHb thresholds.

Modern assessment places greater emphasis on:

• Neurologic condition
• Cardiac involvement
• Loss of consciousness
• Metabolic abnormalities
• Exposure history
• Pregnancy
• Overall severity

Thus:

Treat the patient, not simply the COHb number.

Neurologic Toxicity

Acute CO poisoning can cause:

• Headache
• Dizziness
• Confusion
• Ataxia
• Syncope
• Seizures
• Coma
• Focal neurologic abnormalities

Neurologic findings are important when considering HBOT.

Delayed Neurologic Sequelae

Some patients develop neurologic or neuropsychiatric problems after apparent initial recovery.

Possible manifestations include:

• Cognitive impairment
• Memory difficulty
• Personality or behavioral changes
• Gait abnormalities
• Movement disorders
• Mood symptoms

These can appear after a symptom-free interval.

Whether HBOT reliably prevents delayed neurologic injury remains an area of uncertainty; clinical trials have produced differing results.

Cardiac Toxicity

The myocardium is highly sensitive to CO-related hypoxia.

Possible manifestations include:

• Chest pain
• Ischemic ECG abnormalities
• Elevated cardiac biomarkers
• Dysrhythmias
• Reduced ventricular function
• Cardiogenic shock

Significant myocardial involvement increases concern for severe poisoning and supports early discussion with a hyperbaric specialist.

Pregnancy

Pregnancy deserves special consideration because:

• CO crosses the placenta.
• Fetal hemoglobin binds CO strongly.
• Fetal CO elimination is slower than maternal elimination.
• Maternal COHb does not reliably reflect fetal exposure.

Therefore, clinicians may use a lower threshold for hyperbaric consultation in significant maternal CO poisoning.

Pregnancy itself is not a contraindication to HBOT when clinically indicated.

Smoke Inhalation

A patient exposed to an enclosed-space fire may have several simultaneous problems:

• Carbon monoxide poisoning
• Cyanide toxicity
• Thermal airway injury
• Pulmonary irritant injury
• Burns
• Trauma

HBOT addresses the CO component but does not replace treatment of these other conditions.

Cyanide Poisoning

Older literature proposed HBOT as an adjunct for severe cyanide poisoning.

It is not a primary modern cyanide antidote.

Management instead centers on:

• Airway and ventilation
• High-concentration oxygen
• Hydroxocobalamin
• Supportive cardiovascular care
• Additional antidotal therapy in selected circumstances

HBOT should not delay established cyanide antidotal treatment.

Hydrogen Sulfide Poisoning

HBOT has also been reported in severe hydrogen sulfide poisoning.

However, evidence is limited.

Modern management primarily involves:

• Safe removal from exposure
• High-concentration oxygen
• Ventilatory support
• Cardiovascular support
• Treatment of seizures and other complications

HBOT may occasionally be discussed for exceptionally severe cases, but it is not established routine therapy.

Methemoglobinemia

Methemoglobinemia impairs hemoglobin’s ability to transport and release oxygen effectively.

Standard treatment of clinically significant acquired methemoglobinemia generally involves:

• Removal of the oxidizing agent
• Oxygen
• Methylene blue when appropriate

HBOT is not routine.

It may be considered as an exceptional rescue strategy when severe tissue hypoxia persists and standard treatment is ineffective or unsuitable.

Carbon Tetrachloride and Chloroform

Older reports proposed HBOT for chlorinated hydrocarbon poisoning to reduce hepatic injury.

This is not an established routine modern indication.

Management of these exposures is predominantly supportive and directed toward organ complications.

Severe Anemia

HBOT can dramatically increase dissolved plasma oxygen.

For this reason, it has occasionally been used as a temporary supportive measure in exceptional cases of profound anemia when adequate oxygen-carrying capacity cannot promptly be restored.

This is a specialized nonroutine indication.

Other Established Non-Toxicologic Uses

HBOT also has applications outside poisoning, including selected cases of:

• Decompression sickness
• Arterial gas embolism
• Gas gangrene
• Certain necrotizing infections
• Radiation tissue injury
• Compromised grafts or flaps
• Selected difficult wounds
• Refractory osteomyelitis

Indications depend on current hyperbaric-medicine criteria.

Absolute Contraindication

The major classic absolute contraindication is:

Untreated pneumothorax

During pressure changes, trapped pleural gas can expand and produce life-threatening tension physiology.

A pneumothorax requiring treatment must therefore be appropriately managed before HBOT.

Recent Chest Surgery

Contrary to the older source, recent thoracic surgery is not automatically an absolute contraindication.

Risk depends on factors such as:

• Residual pneumothorax
• Trapped gas
• Surgical anatomy
• Pulmonary condition

The hyperbaric physician should assess these factors individually.

Ear and Sinus Barotrauma

Pressure changes can cause:

• Ear pain
• Middle-ear barotrauma
• Tympanic membrane injury
• Sinus pain
• Sinus barotrauma

Patients must be able to equalize pressure or receive appropriate preventive management.

Middle-ear barotrauma is among the more common HBOT complications.

Pulmonary Barotrauma

Pressure changes can also affect the lungs.

Patients with certain pulmonary disorders, trapped intrathoracic gas, or significant air-space disease require careful assessment.

Pulmonary barotrauma is uncommon but potentially serious.

Oxygen Toxicity

Very high oxygen partial pressures can cause CNS oxygen toxicity.

The most dramatic manifestation is:

• Generalized seizure

An oxygen-toxicity seizure does not necessarily imply permanent neurologic injury, but it requires immediate management of oxygen exposure and patient safety.

Seizure Risk

A history of epilepsy is generally a relative consideration rather than an absolute contraindication.

Other factors that may lower the seizure threshold include:

• Fever
• Certain medications
• Metabolic abnormalities
• Alcohol withdrawal
• Underlying toxicologic illness

Risks must be balanced against the potential benefit of HBOT.

Claustrophobia

Monoplace chambers can provoke:

• Anxiety
• Panic
• Claustrophobia

Preparation and reassurance may help.

Any sedating medication must be used carefully because it can complicate neurologic and respiratory monitoring.

Temporary Visual Changes

Repeated HBOT exposures can produce temporary refractive changes, particularly myopia.

Longer treatment courses can also contribute to ocular effects such as cataract progression.

These issues are more relevant to repeated treatments than to a single emergency session.

Critically Ill Patients

Transporting an unstable poisoned patient to a hyperbaric facility can itself create risk.

The decision must consider:

• Hemodynamic stability
• Airway requirements
• Ventilator compatibility
• Monitoring capability
• Distance and transport time
• Chamber staffing
• Ability to manage deterioration inside the chamber

HBOT should not compromise essential resuscitation.

Monoplace vs Multiplace in Critical Illness

A multiplace chamber may offer an important advantage because trained personnel can remain physically present with the patient.

Monoplace treatment may limit immediate physical access.

Therefore, chamber capabilities matter when treating:

• Intubated patients
• Hemodynamically unstable patients
• Patients requiring continuous interventions

Timing

When HBOT is chosen for acute CO poisoning, early treatment is generally preferred.

However, the decision should not delay:

• High-concentration normobaric oxygen
• Airway stabilization
• Cardiovascular resuscitation
• Treatment of concurrent poisoning or trauma

Monitoring

Depending on illness severity and chamber capabilities, monitoring may include:

• Continuous ECG
• Blood pressure
• Oxygenation
• Ventilation
• Neurologic status
• Airway and ventilator function
• Signs of barotrauma
• Seizure activity

Equipment used inside hyperbaric chambers must meet appropriate safety requirements.

Important Modernization of the Older Source

• HBOT means high-concentration oxygen delivered at greater-than-atmospheric pressure.
• Its principal toxicologic role is selected carbon monoxide poisoning.
• All suspected significant CO poisoning should receive high-concentration oxygen promptly while HBOT is being considered.
• COHb concentration alone does not accurately determine poisoning severity or the need for HBOT.
• Serious neurologic or cardiac manifestations are particularly important in treatment decisions.
• Pregnancy warrants special consideration because fetal CO kinetics differ from maternal kinetics.
• Evidence that HBOT prevents delayed neurologic sequelae is not completely consistent, so treatment decisions remain individualized.
• HBOT is not a substitute for hydroxocobalamin in cyanide poisoning.
• Evidence supporting HBOT for hydrogen sulfide poisoning is limited.
• HBOT is only an exceptional rescue option for severe refractory methemoglobinemia.
• Routine HBOT for carbon tetrachloride or chloroform poisoning is not supported by modern practice.
• Untreated pneumothorax is the major absolute contraindication.
• Recent thoracic surgery is not automatically an absolute contraindication.
• Middle-ear barotrauma is an important common complication.
• CNS oxygen toxicity can cause seizures.
• Transport and chamber limitations must be weighed against potential benefit in unstable patients.
• Historical rigid pressure/time protocols should not be generalized; treatment profiles are determined by experienced hyperbaric teams.

Key Points

• HBOT increases dissolved plasma oxygen by combining high-concentration oxygen with elevated ambient pressure.
• Its main toxicologic application is selected severe carbon monoxide poisoning.
• It accelerates CO elimination and markedly increases tissue oxygen availability.
• CO toxicity involves more than carboxyhemoglobin alone, including mitochondrial, inflammatory, neurologic, and myocardial injury.
• COHb concentration does not correlate reliably enough with severity to determine treatment by itself.
• A normal standard pulse oximeter reading does not exclude CO poisoning.
• Loss of consciousness, major neurologic abnormalities, myocardial injury, severe acidosis, hemodynamic instability, and pregnancy are important factors when considering hyperbaric consultation.
• High-concentration normobaric oxygen should begin immediately and should not be delayed while arranging HBOT.
• HBOT is not routine definitive therapy for cyanide, hydrogen sulfide, chlorinated hydrocarbon poisoning, or methemoglobinemia.
• Untreated pneumothorax is the major absolute contraindication.
• Important adverse effects include ear/sinus barotrauma, oxygen-toxicity seizures, anxiety/claustrophobia, and less commonly pulmonary barotrauma.
• The decision to use HBOT should incorporate poisoning severity, timing, transport risk, chamber capability, and specialist assessment.

Toxicology – Glucagon

Core Concept

Glucagon is an endogenous peptide hormone best known for increasing blood glucose, but it also has positive chronotropic and inotropic cardiac effects.

In toxicology, its traditional major role is as an adjunct in beta-blocker poisoning.

Its role in calcium channel blocker (CCB) poisoning is much less established, and modern management of severe CCB toxicity relies more heavily on calcium, high-dose insulin euglycemia therapy, vasopressors, and other supportive measures.

Normal Physiologic Role

Glucagon is produced by pancreatic alpha cells, particularly in response to falling blood glucose.

Its metabolic effects include:

• Hepatic glycogenolysis
• Hepatic gluconeogenesis
• Increased blood glucose

Its ability to raise glucose depends partly on available hepatic glycogen stores.

Cardiac Mechanism

Glucagon binds to its own G-protein-coupled receptor rather than the beta-adrenergic receptor.

This activates adenylate cyclase:

Glucagon receptor → adenylate cyclase → ↑ cAMP → ↑ intracellular calcium

Cardiac consequences can include:

• Increased heart rate
• Increased contractility
• Improved cardiac output

Why It Can Work in Beta-Blocker Poisoning

Beta blockers inhibit beta-adrenergic receptor signaling.

Normally:

β-receptor stimulation → ↑ cAMP → increased cardiac activity

Glucagon can increase cAMP through a different receptor pathway.

Therefore:

β receptor blocked + glucagon receptor stimulated → cAMP can still increase

This is why glucagon has historically been described as bypassing beta-receptor blockade.

Beta-Blocker Poisoning

Severe beta-blocker toxicity may cause:

• Bradycardia
• Hypotension
• AV conduction abnormalities
• Cardiogenic shock
• Reduced myocardial contractility

Some agents have additional toxic properties.

For example:

• Propranolol can cause sodium-channel blockade and seizures.
• Sotalol can markedly prolong QT and cause torsades de pointes.

These additional mechanisms require their own targeted management.

Role of Glucagon in Beta-Blocker Toxicity

Glucagon can be considered for clinically important beta-blocker-associated:

• Bradycardia
• Hypotension
• Reduced myocardial contractility

A meaningful improvement in heart rate or blood pressure may support continuation of therapy.

However:

Glucagon should not be regarded as the sole or universally effective antidote for severe beta-blocker poisoning.

Evidence supporting its use is limited compared with the strength of its traditional reputation.

Modern Severe Beta-Blocker Management

Treatment is usually multimodal and may include:

• Airway and ventilatory support
• IV fluids when appropriate
• Atropine as an initial temporizing intervention
• Vasopressors
• Glucagon
• High-dose insulin euglycemia therapy (HIE)
• Correction of electrolyte and acid-base abnormalities
• Sodium bicarbonate for significant sodium-channel blockade
• Magnesium/electrical therapy for appropriate ventricular dysrhythmias
• Extracorporeal life support in selected refractory shock

Treatment should be based on the specific beta blocker and hemodynamic phenotype.

High-Dose Insulin Euglycemia Therapy

HIE has become particularly important for severe cardiogenic shock caused by beta blockers and especially calcium channel blockers.

Insulin can improve myocardial carbohydrate utilization and contractility.

Therapy requires close monitoring of:

• Blood glucose
• Potassium
• Hemodynamics
• Fluid balance

Glucagon and HIE are not mutually exclusive; they may be components of the same resuscitation strategy.

Calcium Channel Blocker Poisoning

Older sources frequently recommended glucagon for severe CCB poisoning.

Modern evidence for meaningful benefit is limited.

Severe CCB toxicity more commonly requires:

• IV calcium
• HIE
• Vasopressors
• Airway/ventilatory support
• Careful fluid management
• Selected rescue therapies for refractory cardiovascular collapse

Thus:

Glucagon is not a primary modern antidote for CCB poisoning.

CCB Toxicity and Hyperglycemia

CCBs, particularly severe poisoning with agents such as verapamil or diltiazem, can impair pancreatic insulin release.

This can produce:

• Hyperglycemia
• Insulin deficiency/resistance
• Reduced myocardial carbohydrate utilization

Marked hyperglycemia can therefore be a useful clue to severe CCB toxicity.

This metabolic disturbance is one reason HIE is important.

Hypoglycemia

Glucagon is also used outside toxicology to treat severe hypoglycemia when rapid oral carbohydrate or IV dextrose is not immediately feasible.

It increases glucose primarily by mobilizing hepatic glycogen.

However, its effectiveness may be reduced when glycogen stores are depleted.

Examples include:

• Prolonged fasting
• Severe malnutrition
• Chronic heavy alcohol use
• Advanced liver disease

When reliable IV access exists, dextrose provides a more direct glucose source.

Insulin and Sulfonylurea Poisoning

Glucagon is not the preferred definitive therapy for severe hypoglycemia from insulin or insulin secretagogues.

Insulin toxicity

Management centers on:

• Dextrose
• Frequent glucose monitoring
• Electrolyte monitoring
• Prolonged glucose support when necessary

Sulfonylurea toxicity

Dextrose corrects hypoglycemia, but glucose administration can stimulate further insulin release.

Octreotide is therefore important for recurrent sulfonylurea-induced hypoglycemia.

Glucagon can also stimulate insulin release, making it poorly suited as definitive treatment for sulfonylurea poisoning.

Nausea and Vomiting

A major practical limitation of glucagon is:

Nausea and vomiting are common, particularly when larger amounts are used.

This is especially concerning in poisoned patients with:

• Depressed consciousness
• Poor airway protection
• High aspiration risk

Airway status must therefore be considered carefully.

Hyperglycemia

Glucagon stimulates hepatic glucose release and can cause transient hyperglycemia.

Blood glucose should be monitored, especially when glucagon is being combined with other metabolic therapies.

Hypokalemia

Glucagon-associated metabolic changes can contribute to reductions in serum potassium.

In severe cardiotoxic poisoning, potassium abnormalities are especially important because they can influence:

• Cardiac conduction
• Dysrhythmia risk
• Response to HIE

Serial electrolyte monitoring is appropriate.

Pheochromocytoma

Glucagon can provoke catecholamine release in patients with pheochromocytoma.

This can produce severe:

• Hypertension
• Tachycardia
• Cardiovascular instability

Known pheochromocytoma is therefore an important precaution/contraindication.

Insulinoma

In a patient with an insulinoma, glucagon-induced hyperglycemia can provoke additional insulin secretion.

This may subsequently cause paradoxical or recurrent hypoglycemia.

Hypersensitivity

Serious allergic reactions are uncommon but possible.

Reported reactions include:

• Rash
• Hypersensitivity
• Rare anaphylaxis

Standard emergency treatment is required if a serious reaction occurs.

Warfarin Interaction

Older reports describe enhanced anticoagulant effects when glucagon is used with warfarin.

This is not usually the central concern during emergency toxicologic resuscitation, but coagulation status may be relevant in patients receiving chronic anticoagulation.

Preparation Issues

Severe beta-blocker poisoning historically required amounts of glucagon far greater than those contained in ordinary outpatient hypoglycemia rescue kits.

This can create practical problems with:

• Hospital supply
• Preparation
• Reconstitution
• Administration volume

Pharmacy involvement should occur early if substantial glucagon therapy is being considered.

Modern commercial formulations and diluents vary, so older warnings about a specific phenol-containing diluent should not be generalized to every current glucagon product.

Resource Limitation

One practical reason glucagon cannot be relied upon as the sole treatment of massive beta-blocker poisoning is that hospitals may not have large quantities immediately available.

Resuscitation should therefore proceed simultaneously with other appropriate therapies rather than waiting for glucagon procurement.

Assessing Response

Glucagon treatment should be assessed clinically by changes in:

• Heart rate
• Blood pressure
• Perfusion
• Mental status
• Cardiac output when available

A biochemical effect or transient increase in heart rate without improved perfusion is not necessarily an adequate therapeutic response.

Refractory Shock

If severe beta-blocker or CCB poisoning remains unstable despite initial treatment, escalation may involve:

• Vasopressor optimization
• HIE
• Mechanism-specific treatment
• Bedside echocardiography/hemodynamic assessment
• Toxicology consultation
• Mechanical circulatory support in selected cases

VA-ECMO may be considered in selected patients with otherwise refractory but potentially reversible cardiogenic shock.

Pregnancy

The historical FDA Category B designation is obsolete.

When glucagon is clinically indicated during pregnancy, treatment should be based on maternal condition and expected benefit.

In severe poisoning, restoring maternal circulation and perfusion is the immediate priority.

Monitoring in Cardiotoxic Poisoning

Monitor:

• Continuous ECG
• Heart rate
• Blood pressure
• Perfusion
• Mental status
• Blood glucose
• Potassium and other electrolytes
• Acid-base status
• Renal function
• Fluid balance

Bedside echocardiography can help distinguish predominant myocardial depression from vasodilatory shock and guide therapy.

Important Modernization of the Older Source

• Glucagon increases intracellular cAMP through its own receptor, bypassing beta-adrenergic receptor blockade.
• Its principal toxicologic role is as an adjunct in beta-blocker poisoning.
• The evidence supporting glucagon in beta-blocker poisoning is more limited than older textbooks sometimes imply.
• It should not delay vasopressors, HIE, or other appropriate therapies in severe shock.
• Glucagon has a much less established role in CCB poisoning and is not a primary modern antidote for it.
• HIE has become central to management of severe CCB cardiotoxicity and is also useful in selected severe beta-blocker poisoning.
• Propranolol-associated sodium-channel blockade requires mechanism-specific treatment rather than glucagon alone.
• Sotalol-associated QT prolongation/torsades requires appropriate dysrhythmia management.
• Glucagon is not preferred definitive therapy for insulin or sulfonylurea poisoning.
• Octreotide is particularly important for recurrent sulfonylurea-associated hypoglycemia.
• Nausea and vomiting are common with glucagon and may create aspiration risk.
• Known pheochromocytoma is an important concern because glucagon can provoke catecholamine release.
• Hospital glucagon supply can become a limiting factor in severe poisoning.
• Formulations and diluents have changed; historical phenol-diluent instructions should not automatically be applied to modern products.
• Historical pregnancy letter categories are obsolete.
• Exact high-dose toxicologic regimens should follow current poison-center or medical-toxicology protocols.

Key Points

• Glucagon activates its own receptor → increases cAMP → increases cardiac contractility and heart rate.
• Because this pathway does not require beta-receptor activation, glucagon can partially bypass beta-blockade.
• Its major toxicologic role is an adjunct for severe beta-blocker poisoning.
• Glucagon is not reliably effective enough to be the only treatment for severe beta-blocker shock.
• HIE and vasopressors are major components of modern treatment for severe cardiotoxic poisoning.
• Glucagon has only a limited role in modern CCB poisoning.
• Propranolol and sotalol have additional toxic mechanisms requiring specific treatment.
• Glucagon also raises blood glucose through hepatic glycogenolysis and gluconeogenesis.
• It may be ineffective for hypoglycemia when hepatic glycogen stores are severely depleted.
• Nausea and vomiting are common and can increase aspiration risk.
• Monitor glucose, potassium, ECG, blood pressure, and tissue perfusion.
• Refractory cardiogenic shock may require advanced mechanical circulatory support in selected patients.

Toxicology – Fomepizole (4-Methylpyrazole)

Core Concept

Fomepizole is the preferred antidote for clinically important methanol and ethylene glycol poisoning.

It works by inhibiting alcohol dehydrogenase (ADH), preventing these parent alcohols from being converted into their more dangerous metabolites.

The key principle is:

Fomepizole prevents further toxic-metabolite formation; it does not directly remove metabolites that have already accumulated.

For severe poisoning, hemodialysis may still be required.

Mechanism of Action

Methanol and ethylene glycol initially have relatively limited intrinsic toxicity compared with their metabolites.

Alcohol dehydrogenase initiates their metabolism.

Fomepizole is a potent competitive inhibitor of ADH:

ADH inhibition → ↓ toxic alcohol metabolism → ↓ formation of toxic metabolites

This allows the unchanged parent alcohol to remain available for elimination or removal by dialysis.

Methanol Metabolism

Methanol undergoes:

Methanol → formaldehyde → formic acid/formate

Formate is responsible for much of the severe toxicity, particularly:

• High-anion-gap metabolic acidosis
• Mitochondrial dysfunction
• Optic nerve injury
• Retinal toxicity
• Visual impairment
• CNS injury

Fomepizole prevents additional formation of formate.

Ethylene Glycol Metabolism

Ethylene glycol undergoes:

Ethylene glycol → glycolaldehyde → glycolate → glyoxylate → oxalate

Important toxic consequences include:

• High-anion-gap metabolic acidosis
• Hypocalcemia
• Calcium oxalate formation
• Acute kidney injury
• Neurologic and cardiovascular toxicity

Glycolate is particularly important in producing the metabolic acidosis.

Why Fomepizole Is Preferred Over Ethanol

Both ethanol and fomepizole inhibit toxic-alcohol metabolism.

However, fomepizole offers several practical advantages:

• More predictable ADH inhibition
• Easier administration
• No therapeutic ethanol intoxication
• Less CNS depression
• Lower risk of hypoglycemia
• No need to maintain a therapeutic blood ethanol concentration
• Fewer fluid-management problems
• Easier use in critically ill patients

Therefore:

Fomepizole has largely replaced ethanol as the preferred ADH inhibitor when available.

When to Consider Fomepizole

Treatment should be considered when methanol or ethylene glycol poisoning is sufficiently suspected from findings such as:

• Credible toxic exposure
• Detectable toxic-alcohol concentration of concern
• High-anion-gap metabolic acidosis compatible with toxic alcohol exposure
• Elevated osmolal gap in the appropriate setting
• Characteristic organ toxicity

Treatment decisions should integrate the whole clinical picture rather than rely on one historical concentration cutoff.

Do Not Delay Treatment in a High-Risk Patient

Confirmatory toxic-alcohol concentrations may take considerable time to return.

When serious methanol or ethylene glycol poisoning is strongly suspected:

Fomepizole should be started promptly rather than waiting for definitive laboratory confirmation.

This is particularly important because toxic metabolites may continue to accumulate while testing is pending.

Osmolal Gap

Early in poisoning, unmetabolized parent alcohol may substantially increase the osmolal gap.

As metabolism proceeds:

Parent alcohol ↓ → osmolal gap may ↓

while:

Acidic metabolites ↑ → anion gap ↑

Therefore:

A normal osmolal gap does not exclude methanol or ethylene glycol poisoning, especially later after exposure.

Anion Gap

The development of high-anion-gap metabolic acidosis often reflects accumulation of toxic metabolites.

Important contributors include:

• Formate in methanol poisoning
• Glycolate in ethylene glycol poisoning

However, the anion gap is neither completely sensitive nor specific and must be interpreted with exposure history and other laboratory findings.

Effect of Fomepizole on Toxic-Alcohol Kinetics

Once ADH is inhibited, metabolism slows dramatically.

This is beneficial because toxic metabolite formation stops, but it also means the parent alcohol can remain in the body much longer.

Without dialysis:

Parent toxic-alcohol half-life becomes prolonged.

This does not mean fomepizole has failed; it reflects successful blockade of metabolism.

Methanol Poisoning

Important manifestations can include:

• Nausea and vomiting
• Headache
• Abdominal discomfort
• CNS depression
• High-anion-gap metabolic acidosis
• Blurred vision
• Photophobia
• Visual-field abnormalities
• Severe visual impairment
• Coma in advanced poisoning

Fomepizole prevents further formate production but cannot instantly reverse established optic injury.

Ethylene Glycol Poisoning

Possible manifestations include:

• CNS depression
• Nausea and vomiting
• Tachycardia
• Metabolic acidosis
• Hypocalcemia
• Muscle spasms or tetany
• Seizures in severe cases
• Acute kidney injury

Urinary calcium oxalate crystals may support the diagnosis but are neither required nor sufficiently specific to establish it.

Fomepizole Does Not Correct Existing Acidosis

If substantial toxic metabolites have already accumulated, simply blocking ADH may not rapidly correct the resulting metabolic acidosis.

Management may also require:

• Supportive resuscitation
• Correction of severe acid-base abnormalities
• Electrolyte management
• Hemodialysis when indicated

Hemodialysis

Hemodialysis efficiently removes methanol and ethylene glycol and can remove important circulating toxic metabolites.

It also rapidly corrects:

• Severe metabolic acidosis
• Major electrolyte abnormalities

Dialysis is considered in selected severe poisoning based on factors such as:

• Significant metabolic acidosis
• Serious clinical deterioration
• Visual toxicity from methanol
• Significant kidney injury in ethylene glycol poisoning
• High toxic-alcohol burden
• Other accepted extracorporeal-treatment indications

Modern decisions should use current toxicology and extracorporeal-treatment guidance rather than a single old concentration threshold.

Fomepizole During Hemodialysis

Fomepizole itself is removed by hemodialysis.

Therefore, its administration schedule must be modified during intermittent hemodialysis to maintain adequate ADH inhibition.

The exact adjustment depends on the dialysis modality and current treatment protocol.

Continuous Kidney Replacement Therapy

Continuous extracorporeal therapies differ from intermittent hemodialysis in their clearance of fomepizole and toxic alcohols.

Dose adjustment therefore should not simply copy an intermittent-hemodialysis regimen.

Current poison-center, nephrology, pharmacy, or toxicology guidance should be followed.

Folate in Methanol Poisoning

Methanol metabolism produces formate.

Folic acid or leucovorin may be used as an adjunct because folate-dependent pathways facilitate conversion of formate toward carbon dioxide and water.

Folate does not replace:

• Fomepizole
• Correction of severe acidosis
• Dialysis when indicated

Adjuncts in Ethylene Glycol Poisoning

Thiamine and pyridoxine have historically been administered to favor metabolism of glyoxylate toward less toxic products.

Their clinical importance is secondary to:

• ADH inhibition
• Supportive care
• Management of acidosis
• Hemodialysis when required

They should never delay definitive therapy.

Concurrent Ethanol

Ethanol also competes for alcohol dehydrogenase.

A patient who has simultaneously consumed ethanol may therefore show delayed development of methanol or ethylene glycol toxicity.

As ethanol disappears:

ADH becomes available → toxic alcohol metabolism increases → toxic metabolites accumulate

Thus an initially well-appearing patient can subsequently deteriorate.

Fomepizole and Ethanol Together

Concurrent ethanol exposure is not, by itself, a reason to withhold fomepizole when fomepizole is clinically indicated.

Fomepizole can inhibit ethanol metabolism and prolong ethanol elimination.

The older concept that a measurable ethanol concentration constitutes an absolute contraindication to fomepizole is therefore too rigid.

Clinical monitoring is required.

Adverse Effects

Fomepizole is generally well tolerated.

Reported effects include:

• Headache
• Nausea
• Dizziness
• Vertigo
• Gastrointestinal symptoms
• Mild transient liver-enzyme abnormalities
• Injection-related reactions

Serious adverse effects are uncommon relative to the consequences of untreated toxic-alcohol poisoning.

Hypersensitivity

Fomepizole should be used cautiously or avoided in patients with a convincing history of serious hypersensitivity to:

• Fomepizole
• Closely related pyrazole compounds

In life-threatening toxic-alcohol poisoning, management requires immediate specialist consideration of alternative ADH blockade and extracorporeal therapy.

Pregnancy

The historical FDA Category C classification is obsolete.

Methanol and ethylene glycol can cause severe maternal and fetal toxicity.

Therefore:

Necessary treatment should not be withheld solely because the patient is pregnant.

Fomepizole may be used when the expected benefit of preventing toxic-metabolite formation outweighs potential treatment risk.

Maternal stabilization is the priority.

Pediatric Poisoning

The same fundamental toxicology applies in children:

Prevent toxic-metabolite formation early.

Children with significant suspected methanol or ethylene glycol poisoning require urgent specialist management.

Treatment is based on weight, clinical severity, laboratory abnormalities, and extracorporeal therapy requirements.

Monitoring

Important monitoring includes:

• Mental status
• Airway and ventilation
• Blood pressure and perfusion
• Blood gas
• Bicarbonate
• Anion gap
• Electrolytes
• Glucose
• Renal function
• Osmolality/osmolal gap when useful
• Methanol or ethylene glycol concentration when available

Additional monitoring depends on the suspected alcohol.

Methanol-Specific Monitoring

Pay particular attention to:

• Visual symptoms
• Visual acuity when feasible
• Neurologic deterioration
• Severity of metabolic acidosis

Severe visual toxicity is an important marker of clinically significant formate exposure.

Ethylene Glycol-Specific Monitoring

Pay particular attention to:

• Creatinine
• Urine output
• Calcium
• Neuromuscular manifestations of hypocalcemia
• Evidence of acute kidney injury

Urinary crystals may be sought but should not determine treatment by themselves.

Stopping Fomepizole

Therapy should not be stopped merely because the patient appears clinically improved.

Discontinuation depends on factors such as:

• Toxic-alcohol concentration
• Resolution of clinically important acidosis
• Clinical stability
• Completion of dialysis when applicable
• Confidence that ongoing toxic-metabolite production is no longer clinically important

Current institutional or poison-center protocols should guide the endpoint.

Important Modernization of the Older Source

• Fomepizole is generally the preferred antidote for methanol and ethylene glycol poisoning.
• It inhibits alcohol dehydrogenase and prevents formation of additional toxic metabolites.
• It does not directly neutralize formate, glycolate, or oxalate already produced.
• Severe poisoning may therefore still require hemodialysis despite timely fomepizole.
• Treatment should not be delayed for confirmatory toxic-alcohol levels when clinical suspicion is high.
• A normal osmolal gap does not exclude late poisoning.
• The osmolal gap tends to be more prominent while parent alcohol remains, whereas the anion gap rises as acidic metabolites accumulate.
• Historical fixed concentration thresholds should not be used as the sole basis for starting antidote or dialysis.
• Fomepizole substantially prolongs the elimination of unmetabolized methanol and ethylene glycol when dialysis is not performed.
• Hemodialysis removes fomepizole, so the administration schedule must be adjusted during extracorporeal therapy.
• Concurrent ethanol is not an absolute contraindication to fomepizole.
• Fomepizole can slow ethanol elimination.
• Folate is an adjunct for methanol poisoning.
• Thiamine and pyridoxine are secondary adjuncts in ethylene glycol poisoning and should not distract from definitive treatment.
• Historical FDA pregnancy categories are obsolete.
• Exact dosing and dialysis adjustments should follow current toxicology, pharmacy, and extracorporeal-treatment protocols rather than older fixed regimens.

Key Points

• Fomepizole inhibits alcohol dehydrogenase.
• It is the preferred antidote for significant methanol and ethylene glycol poisoning.
• Methanol toxicity is largely caused by formate, particularly producing acidosis and optic toxicity.
• Ethylene glycol toxicity is largely caused by metabolites including glycolate and oxalate, producing acidosis and renal injury.
• Fomepizole prevents additional toxic-metabolite formation but does not remove metabolites already present.
• A normal osmolal gap does not exclude toxic-alcohol poisoning.
• Do not delay treatment in a strongly suspected severe exposure while waiting for definitive levels.
• Hemodialysis may still be necessary for severe poisoning.
• Fomepizole is dialyzable, requiring protocol-specific adjustment during hemodialysis.
• Folate is an adjunct in methanol poisoning.
• Concurrent ethanol can delay toxic-alcohol manifestations and can itself persist longer after fomepizole.
• Fomepizole is generally safer and easier to manage than therapeutic ethanol.

Toxicology – Calcium Disodium EDTA (CaNa₂EDTA)

Core Concept

Calcium disodium ethylenediaminetetraacetate (CaNa₂EDTA) is a parenteral metal chelator used primarily for significant lead poisoning.

The most important safety distinction is:

CaNa₂EDTA ≠ disodium EDTA (Na₂EDTA).

They are not interchangeable. Disodium EDTA can chelate circulating calcium and cause profound, potentially fatal hypocalcemia.

For lead poisoning, the formulation of interest is calcium disodium EDTA.

Mechanism of Action

CaNa₂EDTA contains calcium already incorporated into the chelator complex.

Lead has a greater affinity for EDTA than calcium does, so lead can displace calcium:

CaNa₂EDTA + Pb → Pb–EDTA complex

The resulting lead chelate is water soluble and eliminated predominantly through the kidneys.

This increases urinary lead excretion and lowers the readily exchangeable lead burden.

What Chelation Does

Chelation can reduce circulating and accessible tissue lead.

However, it does not instantly remove the entire body burden because substantial lead may be stored in:

• Bone
• Teeth
• Soft tissues

Lead can later redistribute from these compartments back into blood.

Therefore, rebound in blood lead concentration after chelation is expected to some degree and does not automatically indicate treatment failure.

Lead Toxicity

Lead interferes with numerous cellular processes, including:

• Heme synthesis
• Enzyme function
• Calcium-dependent signaling
• Mitochondrial function
• Neurologic development

Children are particularly vulnerable to the neurodevelopmental effects of chronic exposure.

Clinical Features of Lead Poisoning

Possible manifestations include:

Neurologic

• Irritability
• Behavioral or cognitive changes
• Headache
• Peripheral neuropathy
• Encephalopathy
• Seizures
• Coma in severe poisoning

Gastrointestinal

• Abdominal pain
• Constipation
• Nausea
• Vomiting
• Anorexia

Hematologic

• Anemia
• Impaired heme synthesis

Renal

• Tubular dysfunction
• Chronic nephropathy with substantial exposure

Lead Encephalopathy

Lead encephalopathy is a medical emergency.

Possible findings include:

• Persistent vomiting
• Altered mental status
• Ataxia
• Seizures
• Cerebral edema
• Coma

Treatment requires urgent specialist-directed chelation and intensive supportive care.

Role of CaNa₂EDTA

CaNa₂EDTA is most important when significant lead poisoning requires parenteral chelation, particularly when:

• Severe toxicity is present
• Oral treatment cannot be used reliably
• Lead encephalopathy is present as part of a specialist-directed regimen

For many patients with less severe poisoning who can tolerate oral therapy, succimer (DMSA) is generally easier to administer and better tolerated.

Severe Lead Encephalopathy

Historically and in current specialist practice, severe lead encephalopathy may require combination parenteral chelation.

Dimercaprol (BAL) plus CaNa₂EDTA has traditionally been used for severe lead encephalopathy.

CaNa₂EDTA should not casually be used as unsupervised monotherapy in this setting.

The exact regimen should follow current toxicology/poison-center protocols.

Why BAL Historically Precedes CaNa₂EDTA

Older practice recommends beginning dimercaprol before CaNa₂EDTA in lead encephalopathy.

This approach arose partly from concern about redistribution of lead during EDTA chelation and the possibility of worsening CNS exposure.

Although the evidence base is largely historical, combination therapy remains an established approach for severe encephalopathic lead poisoning.

Succimer

Succimer (DMSA) is an oral chelator used for many cases of lead poisoning when oral treatment is appropriate.

Advantages include:

• Oral administration
• Generally better tolerability
• Less invasive treatment

However, severe encephalopathy requires a different approach and should not be managed simply with oral succimer.

Chelation Is Not Based on Symptoms Alone

The decision to chelate depends on:

• Confirmed venous blood lead concentration
• Symptoms
• Patient age
• Presence of encephalopathy
• Ability to tolerate oral treatment
• Ongoing exposure
• Renal function

Modern blood-lead thresholds and public-health recommendations have changed considerably since older toxicology texts were written.

Historical cutoffs should therefore not be applied automatically.

Blood Lead Level

A venous blood lead level (BLL) is the primary laboratory test used to assess lead exposure.

Capillary screening can be contaminated by environmental lead on the skin, so elevated screening results generally require appropriate venous confirmation.

Treatment decisions should use current age-specific and public-health guidance.

Removing the Source Is Essential

Chelation cannot compensate for continued lead exposure.

Management must identify and eliminate the source, such as:

• Lead-containing paint or dust
• Contaminated soil
• Occupational exposure
• Contaminated traditional remedies
• Certain cosmetics
• Lead-containing cookware or ceramics
• Retained lead-containing foreign material

If exposure continues, blood lead concentrations can rise again despite successful chelation.

Renal Elimination

The lead–EDTA complex is primarily eliminated in urine.

Therefore, renal function is crucial during therapy.

Monitor:

• Creatinine
• Urine output
• Hydration
• Electrolytes
• Urinalysis when appropriate

Significant renal dysfunction complicates therapy and requires specialist management.

Nephrotoxicity

An important adverse effect of CaNa₂EDTA is renal tubular injury.

Risk increases with:

• Excessive exposure to the chelator
• Dehydration
• Preexisting renal impairment
• Prolonged or repeated treatment

Renal injury is often reversible when recognized promptly and treatment is appropriately modified.

Hydration

Adequate hydration and renal perfusion are important during CaNa₂EDTA therapy.

However, fluid administration should be individualized rather than targeting a rigid urine-output number in every patient.

Excessive fluid administration can itself cause complications.

Loss of Essential Metals

CaNa₂EDTA is not perfectly selective for lead.

It can increase urinary loss of other metals, especially:

• Zinc

Other trace-metal effects may also occur.

This becomes particularly relevant during repeated or prolonged chelation.

Other Adverse Effects

Reported effects include:

• Malaise
• Fatigue
• Fever or chills
• Headache
• Myalgia
• Rash
• Nasal symptoms
• Lacrimation
• Urinary frequency
• Glycosuria
• Hypotension

Serious toxicity is more likely with inappropriate formulation, excessive treatment, or impaired renal clearance.

Extravasation

CaNa₂EDTA can cause local tissue injury if it extravasates.

Possible findings include:

• Pain
• Swelling
• Inflammation
• Local calcium deposition or calcification

If extravasation occurs, stop administration through the affected line and manage according to an appropriate extravasation protocol.

Critical Medication Error – Disodium EDTA

One of the most important points in this entire topic is avoiding confusion between:

Calcium disodium EDTA

CaNa₂EDTA

Used for lead chelation.

Disodium EDTA

Na₂EDTA

Can bind calcium aggressively.

Accidental administration of disodium EDTA instead of CaNa₂EDTA can cause:

Rapid hypocalcemia → tetany/seizures → QT abnormalities/dysrhythmias → cardiac arrest

Fatal medication errors have occurred from confusing these formulations.

EDTA Provocation Testing

The older source describes an EDTA provocation test, in which chelator was administered and urinary metal excretion subsequently measured.

This practice is now obsolete.

Provoked urine testing is not recommended for diagnosing lead poisoning or deciding whether chelation is necessary.

Giving a chelator will predictably increase urinary metal excretion, making the resulting measurement difficult or impossible to interpret against normal unprovoked reference ranges.

Do Not Use Chelation as a Diagnostic Test

Modern principle:

Diagnose exposure first → then determine whether chelation is indicated.

Do not administer CaNa₂EDTA merely to see whether urinary lead increases.

Diagnosis should instead rely on:

• Exposure history
• Confirmed venous BLL
• Clinical findings
• Appropriate additional testing

EDTA for Atherosclerosis

EDTA has been promoted in some alternative-medicine settings as a treatment for:

• Atherosclerosis
• Coronary artery disease
• General “detoxification”

These uses are separate from established toxicologic lead chelation.

CaNa₂EDTA should not be regarded as a general-purpose detoxification agent.

Chelation without a legitimate indication can cause significant harm.

Lead-Containing Foreign Bodies

Some lead exposures involve retained material in the gastrointestinal tract or body.

Examples can include:

• Ingested lead objects
• Lead-containing paint chips
• Retained bullets or fragments in selected circumstances

Management depends on:

• Location
• Whether lead is being absorbed
• Blood lead concentration
• Symptoms
• Feasibility and risk of removal

Chelation alone may be insufficient if an ongoing internal source remains.

Pregnancy

The historical pregnancy classification approach in the source is outdated.

Lead crosses the placenta and can harm both the pregnant patient and fetus.

Chelation decisions during pregnancy therefore require individualized specialist assessment based on:

• Severity of maternal toxicity
• BLL
• Gestational stage
• Risks of continued lead exposure
• Risks and benefits of the available chelator

Serious maternal lead toxicity should not go untreated solely because of pregnancy.

Monitoring During CaNa₂EDTA Therapy

Important monitoring includes:

• Clinical neurologic status
• Venous blood lead concentration
• Renal function
• Urine output
• Hydration status
• Electrolytes
• Urinalysis when indicated
• CBC when appropriate
• Evidence of continued environmental exposure

Repeated courses require careful reassessment.

Rebound After Chelation

After chelation ends, BLL can increase again because lead redistributes from tissue and bone stores into blood.

Therefore, follow-up BLL testing is important.

A substantial rise should also prompt investigation for:

• Continued environmental exposure
• Incomplete source removal
• Retained internal lead source

Repeated chelation without eliminating exposure is not an adequate long-term strategy.

Chelation Does Not Reverse All Lead Injury

Lowering the blood lead concentration does not guarantee reversal of established neurologic injury.

This is especially important in children, where chronic lead exposure can affect neurodevelopment.

The best treatment remains:

Prevention and complete removal of the exposure source.

Important Modernization of the Older Source

Several historical recommendations need updating:

• The correct lead-chelating formulation is calcium disodium EDTA (CaNa₂EDTA).
• It must never be confused with disodium EDTA, which can produce fatal hypocalcemia.
• CaNa₂EDTA is mainly used for significant lead poisoning requiring parenteral chelation.
• Oral succimer is preferred for many appropriate non-encephalopathic cases.
• Severe lead encephalopathy requires urgent specialist-directed therapy; BAL plus CaNa₂EDTA remains a traditional parenteral approach.
• Historical fixed BLL cutoffs should not automatically be applied to contemporary patients because lead-management recommendations have evolved.
• CaNa₂EDTA is nephrotoxic and requires renal monitoring.
• Chelation increases loss of essential trace metals, especially zinc.
• EDTA provocation testing is obsolete and should not be used to diagnose metal toxicity.
• Provoked urinary metal concentrations should not be compared with ordinary reference ranges.
• Chelation should not be used as nonspecific “detoxification.”
• Eliminating the lead source is essential; otherwise toxicity can recur.
• BLL may rebound after treatment because of redistribution from tissue stores.
• Pregnancy requires individualized risk-benefit assessment rather than application of an obsolete FDA letter category.
• Exact chelation schedules should follow current toxicology and poison-center guidance rather than historical fixed regimens.

Key Points

• CaNa₂EDTA is a parenteral chelator used primarily for significant lead poisoning.
• Lead displaces calcium from the EDTA complex and is subsequently eliminated as a urinary chelate.
• Calcium disodium EDTA and disodium EDTA are completely different from a safety standpoint.
• Disodium EDTA can cause profound, potentially fatal hypocalcemia.
• Succimer is generally preferred when an appropriate patient can receive oral chelation.
• Severe lead encephalopathy requires urgent specialist management and may require BAL plus CaNa₂EDTA.
• Renal elimination makes kidney function and hydration important during treatment.
• Nephrotoxicity is a major adverse effect of CaNa₂EDTA.
• CaNa₂EDTA can increase zinc and other trace-metal losses.
• EDTA provocation testing is obsolete.
• Chelation should never substitute for identification and elimination of the lead source.
• Blood lead concentrations can rebound after chelation because lead redistributes from tissue and bone.
• Established neurologic injury may not completely reverse even after successful chelation.

Toxicology – Edrophonium

Core Concept

Edrophonium is an ultra-short-acting, reversible acetylcholinesterase inhibitor.

By temporarily preventing acetylcholine breakdown, it increases acetylcholine at:

• Neuromuscular junctions
• Parasympathetic muscarinic synapses
• Autonomic ganglia

Historically, edrophonium was best known for the Tensilon test for myasthenia gravis and for reversal of nondepolarizing neuromuscular blockade.

Its role in modern medicine and toxicology is now very limited. The traditional diagnostic Tensilon test has largely been replaced by safer and more specific testing, and edrophonium is not a routine treatment for neurotoxic snakebite.

Mechanism of Action

Acetylcholinesterase normally hydrolyzes acetylcholine within the synaptic cleft.

Edrophonium reversibly inhibits this enzyme:

AChE inhibition → ↓ acetylcholine breakdown → ↑ synaptic acetylcholine

At the neuromuscular junction, the increased acetylcholine can temporarily improve transmission when postsynaptic nicotinic receptors are incompletely available or competitively blocked.

Rapid, Short-Lived Action

Edrophonium has:

• Very rapid onset
• Very short duration

This historically made it attractive as a diagnostic drug because any improvement or adverse cholinergic effect appeared quickly and generally resolved relatively rapidly.

Its short action also limits its usefulness as sustained therapy.

Historical Myasthenia Gravis Testing

Myasthenia gravis is an autoimmune disorder of neuromuscular transmission, most commonly involving antibodies against components of the postsynaptic neuromuscular junction.

Typical manifestations include:

• Ptosis
• Diplopia
• Bulbar weakness
• Fatigable skeletal-muscle weakness
• Respiratory weakness in severe disease

Historically, transient improvement after edrophonium supported the diagnosis.

Why the Tensilon Test Is Largely Obsolete

Edrophonium testing has major limitations:

• False-positive and false-negative responses can occur.
• Interpretation can be subjective.
• Bradycardia and other cholinergic complications can occur.
• More specific diagnostic methods are now available.

Modern evaluation may include:

• Acetylcholine-receptor antibodies
• MuSK antibodies
• Other relevant antibody testing
• Repetitive nerve stimulation
• Single-fiber electromyography
• Clinical neurologic assessment

Therefore, the historical Tensilon test is no longer a routine first-line diagnostic test.

Nondepolarizing Neuromuscular Blockade

Nondepolarizing neuromuscular blockers competitively antagonize nicotinic acetylcholine receptors at the neuromuscular junction.

Increasing acetylcholine can compete with these drugs.

Thus:

Edrophonium → ↑ ACh → competition with nondepolarizing blocker → improved neuromuscular transmission

This explains its historical use for postoperative reversal.

Modern Reversal of Neuromuscular Blockade

Edrophonium is now rarely used for this purpose.

Modern anesthesia more commonly uses:

• Neostigmine for appropriate nondepolarizing blockade
• Sugammadex for selected aminosteroid neuromuscular blockers such as rocuronium and vecuronium

Choice depends on the blocker, depth of blockade, patient characteristics, and available agents.

Snakebite – Historical Role

Older literature described edrophonium or other acetylcholinesterase inhibitors for neuroparalytic snake envenomation.

The theoretical mechanism is:

More acetylcholine at the neuromuscular junction → partial competition against postsynaptic neurotoxin-mediated receptor blockade

This approach can sometimes temporarily improve weakness caused by certain postsynaptic neurotoxins.

Why Response Depends on Venom Mechanism

Snake neurotoxins do not all work at the same site.

Postsynaptic Neurotoxins

These interfere with nicotinic acetylcholine receptors.

Increasing acetylcholine may sometimes improve neuromuscular transmission.

Presynaptic Neurotoxins

These damage or disrupt acetylcholine release from the nerve terminal.

If acetylcholine is not being released adequately, simply preventing its breakdown is much less useful.

Therefore:

A response to an acetylcholinesterase inhibitor depends strongly on the venom’s neurotoxic mechanism.

Modern Neurotoxic Snakebite Management

Management centers on:

• Airway assessment
• Close respiratory monitoring
• Early ventilatory support when necessary
• Appropriate species/regional antivenom
• General supportive care

Anticholinesterase therapy is not a substitute for antivenom or mechanical ventilation.

If considered at all, it should be used only in selected neurotoxic envenomations under specialist guidance.

Cholinergic Effects

Because edrophonium raises acetylcholine concentrations, excessive activity can produce a cholinergic syndrome.

Muscarinic manifestations may include:

• Salivation
• Lacrimation
• Sweating
• Nausea
• Vomiting
• Abdominal cramping
• Diarrhea
• Bronchial secretions
• Bronchoconstriction
• Bradycardia
• Hypotension

Pulmonary secretions and bradycardia are particularly important acute complications.

Nicotinic Effects

Excessive acetylcholine at the neuromuscular junction can eventually impair rather than improve transmission.

Possible manifestations include:

• Fasciculations
• Muscle weakness
• Respiratory muscle weakness

Thus, excessive acetylcholinesterase inhibition can paradoxically worsen neuromuscular function.

Respiratory Failure

Respiratory deterioration following edrophonium can result from:

• Bronchorrhea
• Bronchospasm
• Upper-airway secretions
• Respiratory muscle weakness
• Progression of the underlying neuromuscular disorder

In snakebite, this creates an important diagnostic problem because venom-induced paralysis and excessive cholinergic activity may coexist.

Airway and ventilation take priority over trying to distinguish them at the bedside.

Bradycardia

Edrophonium can increase parasympathetic activity at the heart.

This can cause:

• Sinus bradycardia
• AV conduction slowing
• Hypotension
• Rarely profound bradycardia or cardiac arrest

Continuous ECG monitoring is appropriate when edrophonium is used in a setting where significant cardiovascular effects are possible.

Atropine

Atropine antagonizes the muscarinic effects of excessive acetylcholine.

It can therefore counter manifestations such as:

• Severe bradycardia
• Excessive bronchial secretions
• Other important muscarinic effects

However:

Atropine does not reverse nicotinic skeletal-muscle weakness.

This distinction is important in both cholinesterase-inhibitor toxicity and neurotoxic snakebite.

Organophosphate and Carbamate Poisoning

Edrophonium should not be used to treat these poisonings.

Organophosphates and carbamates already inhibit acetylcholinesterase.

Adding another acetylcholinesterase inhibitor can worsen:

• Bronchorrhea
• Bronchospasm
• Bradycardia
• Secretions
• Cholinergic neuromuscular dysfunction

For significant organophosphate poisoning, modern therapy instead centers on:

• Airway and ventilation
• Atropine
• Pralidoxime when appropriate
• Benzodiazepines for seizures

Interaction With Other Anticholinesterases

Additive cholinergic effects can occur with agents such as:

• Neostigmine
• Pyridostigmine
• Physostigmine
• Other acetylcholinesterase inhibitors

Excessive combined activity can produce a cholinergic crisis.

Cardiac Disease and Drug Interactions

Patients taking medications that already slow cardiac conduction may be more vulnerable to clinically important bradycardia.

Examples include selected:

• Beta blockers
• Calcium channel blockers
• Digoxin

The interaction is primarily important because several mechanisms may simultaneously depress heart rate or AV conduction.

Myasthenic vs Cholinergic Crisis

Historically, edrophonium was sometimes used in an attempt to distinguish these syndromes.

Myasthenic Crisis

Severe weakness due to inadequate neuromuscular transmission from myasthenia gravis.

Cholinergic Crisis

Weakness resulting from excessive acetylcholinesterase inhibition.

The historical idea was that edrophonium might briefly improve myasthenic weakness while worsening cholinergic weakness.

In modern practice, this approach is generally avoided because it can be unreliable and potentially dangerous.

Respiratory support and specialist evaluation are more important.

Hypotension

Hypotension can accompany excessive cholinergic activity, especially when associated with bradycardia.

Management focuses on:

• Airway and breathing
• Appropriate IV fluid resuscitation
• Treatment of severe muscarinic effects
• Vasopressor support when necessary

The older routine recommendation for Trendelenburg positioning is obsolete and should not substitute for proper shock management.

Seizures

Seizures are not a typical therapeutic effect of edrophonium but can occur in severe toxic states or from other underlying causes.

If seizures occur:

Benzodiazepines are generally first-line therapy for toxicologic seizures.

Routine phenytoin is not the preferred general second-line strategy for toxin-induced seizures.

Pregnancy

The historical FDA pregnancy Category C designation is obsolete.

Use during pregnancy should depend on:

• Clinical necessity
• Maternal condition
• Availability of safer or better-established alternatives

For life-threatening neuromuscular or toxicologic emergencies, maternal stabilization remains the priority.

Monitoring

When edrophonium is used, monitor:

• Airway
• Respiratory effort
• Bronchial secretions
• Oxygenation and ventilation
• Heart rate
• ECG
• Blood pressure
• Skeletal-muscle strength
• Signs of excessive cholinergic activity

In neurotoxic snakebite, serial assessment of respiratory muscle function is particularly important.

Important Modernization of the Older Source

Several historical recommendations require substantial revision:

• Edrophonium is a short-acting reversible acetylcholinesterase inhibitor.
• The traditional Tensilon test for myasthenia gravis is largely obsolete.
• Modern myasthenia diagnosis relies more heavily on antibody testing, electrodiagnostic studies, and clinical assessment.
• Edrophonium is rarely used for reversal of postoperative neuromuscular blockade; neostigmine and sugammadex have largely replaced it in modern anesthesia practice.
• Anticholinesterase therapy is not routine treatment for neurotoxic snakebite.
• Selected postsynaptic neurotoxic envenomations may respond to an acetylcholinesterase inhibitor, whereas presynaptic neurotoxicity generally responds poorly.
• Appropriate antivenom and respiratory support remain the central treatments for serious neurotoxic snakebite.
• Edrophonium can itself produce dangerous cholinergic toxicity, including bronchorrhea, bradycardia, hypotension, and respiratory weakness.
• Atropine reverses dangerous muscarinic effects but does not correct nicotinic paralysis.
• Edrophonium should not be added to organophosphate or carbamate poisoning.
• Trendelenburg positioning is not modern definitive treatment for toxicologic hypotension.
• Historical fixed dosing regimens should not be generalized to contemporary snakebite management.

Key Points

• Edrophonium is an ultra-short-acting reversible acetylcholinesterase inhibitor.
• It increases acetylcholine at cholinergic synapses and the neuromuscular junction.
• Its historical diagnostic use in myasthenia gravis has largely been replaced by modern antibody and electrophysiologic testing.
• Its historical role in postoperative reversal has also largely been replaced by other agents.
• Edrophonium has only a limited, specialist-directed role in selected neurotoxic snake envenomations.
• Postsynaptic neurotoxic blockade is more likely to respond than presynaptic neurotoxicity.
• Antivenom and respiratory support are more important than anticholinesterase therapy in serious snakebite.
• Excess edrophonium can cause a cholinergic syndrome.
• Dangerous effects include bronchial secretions, bronchospasm, bradycardia, hypotension, and respiratory weakness.
• Atropine treats muscarinic toxicity but not nicotinic skeletal-muscle paralysis.
• Edrophonium can worsen organophosphate or carbamate poisoning.
• Airway and ventilation are the priorities whenever neuromuscular respiratory failure is developing.